書籍詳細

I. 体外循環血液浄化法

P.5 掲載の参考文献

• 1) 川口良人, 和田孝雄:透析導入のガイドラインの策定と追跡調査に関する研究. 平成4年度厚生科学研究「腎不全医療研究事業」研究報告書 三村信英編:156-164, 1993.

P.19 掲載の参考文献

• 1) Schreiner GE:The search for the uremic toxin (s). Kidney Int 7 (Suppl. 3):s 270-s 271.1975.

• 2) Sargent JA:Control of dialysis by a single pool urea model:the National Cooperative Dialysis Study. Kidney Int 23 (Suppl. 13):s 19-s 25.1983.

• 3) Lowrie EG, Laird NM, Parker TF, et al:Effect of hemodialysis prescription on patient mobidity. N Eng J Med 305 (20):1176-1181, 1981.

• 4) Shapiro JI, Argy WP, Rakowski TA, et al:The unsuitability of BUN as a criterion for prescription dialysis. Trans Am Soc Artif Intern Organs 29:129-132.1983.
  pubmed

• 5) Avram MM, Slater PA, Gan A, et al:Predialysis BUN and creatinine do not adequate predict dialysis, clinical rehabilitaiton, or longevity. Kidney Int 28 (Suppl. 17):s 100-s 104, 1985.
  pubmed

• 6) Gotch FA, Sargent JA:A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 28:526-534, 1985.
  pubmed

• 7) Babb AL, Popovich RP, Christopher TG, et al:The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Intern Organs 17:81-91, 1971.
  pubmed

• 8) Babb AL, Strand MJ, Uvelli DA, et al:Quantitative description of dialysis treatment:A dialysis index. Kidney Int 7 (Suppl. 2):s 23-s 29, 1975.

• 9) Klinkman H:General conditions of the meeting (middle molecules in uremia and other diseases):where do we go from here. Artif Organs 4 (Suppl.):1988, 1981.

• 10) Charra B, Calemard E, Ruffet M, et al:Survival as an index of adequacy of dialysis. Kidney Int 41:1286-1291, 1992.
  pubmed

• 11) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現状 (1993年12月31日現在). 名古屋, 1994.

• 12) Canbi V, Arisi L, Buzio C, et al:Intensive utilisation of a dialysis unit. Proc Eur Dial Transplant Assoc 10:342-346, 1973.

• 13) Hull AR, Parker TE:Introduction and summmary to proceedings from the morbidity, mortality and prescription of dialysis symposium. Am J Kidney Dis 15 (5):375-383, 1990.

• 14) Sargent JA:Shortfalls in the delivery of dialysis. Am J Kidney Dis 15 (5):500-510, 1990.
  pubmed

• 15) Gotch FA, Yarian S, Keen M:Akinetic study of US hemodialysis prescriptions. Am J Kidney Dis 15 (5):511-515, 1990.

• 16) Gotch FA:Dialysis of the future. Kidney Int 33 (Suppl. 24):s 100-s 104, 1988.

• 17) Collins AJ, Kjellstrand CM:Shortning of the hemodialysis procedure and mortality in "healthy" dialysis patients. Trans Am Soc Artif Intern Organs 36:145-148, 1990.

• 18) Wizemann V:Present clinical experience and future aspects of haemodiafiltration:in Cambi V (ed):Short dialysis. Boston. Nijhoff, 293-320, 1787.

• 19) Held PJ, Levin NW, Bovbjerg RR, et al:Mortality and duration of hemodialysis treatment. JAMA 265 (7):871-875, 1991.
  pubmed

• 20) Laurent G, Calemard E, Charra B:Long dialysis:a review of fifteen years experience in one centre 1968-1983.Proc EDTA 20:122-129, 1983.

• 21) Jeevanandam M, Legaspi A, Lowry SF, et al:Effect of total parenteral nutrition on whole body protein kinetics in cachectic patients with benign or malignant disease. J Paren Enteral Nutr 12:229-236, 1988.
  pubmed

• 22) Borrah MF, Schoenfeld PY, Gotch FA, et al:Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 14:491-500, 1978.

• 23) Acchiardo SR, Moore LW, Latour PA:Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int 24 (Suppl. 16):s 199-s 203, 1983.

• 24) Lowrie EG, Lew NL:Death risk in hemodialysis patients:the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15(5):458-482, 1990.

• 25) Crockcroft DW, Gault MH:Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976.

• 26) Degoulet P, Legrain M, Rlach I, et al:Mortality risk factors in patients treated by chronic hemodialysis. Nephron 31:103-110, 1982.

• 27) Chazan JA, Lew NL, Lowrie EG:Increased serum aluminun. Arch Intern Med 151:319-322, 1991

P.27 掲載の参考文献

• 1) わが国の慢性透析療法の現況 (1993年12月31日現在):日本透析医学会統計調査委員会.

• 2) Lowrie EG, Laird NM, Parker TF, et al:Effect of the hemodialysis prescription on patient morbility:Report from the National Cooperative Dialysis Study. N Engl J Med 305:1176, 1981.

• 3) Larid NM, Berkey CS, Lowrie EG, et al:Modeling success or failure of dialysis therapy:The National Cooperative Dialysis Study. Kidney Int 23 (suppl. 13):101, 1983.

• 4) Babb AL, Popovich PP, Christopher TG, et al:The genesis of the square meter-hour hypothesis. Trans. Am. Soc. Artif. Intern Organs 17:81, 1971.

• 5) Gejyo F, Yamada T, Odani S, et al:A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem. Biophys. Res Commum 129;701, 1985.

• 6) Miyata T, Oda O, Inagi R, et al:β2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243, 1993.

• 7) Miyata T, Inagi R, Iida Y, et al:Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 93:521;1994.

• 8) Gejyo F, Homma N, Suzuki Y, et al:Serum levels of β2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 314:585, 1986.

• 9) Zingraff JJ, Noel LH, Bardin T, et al:β2-microglobulin amyloidosis in chronic renal failure. N Engl J Med 323; 1070, 1990.

• 10) Hakim RM, Fearon DT, Lazarus JM:Biocompatibility of dialysis membranes:Effects of chronic complement activation. Kidney Int 26;194, 1984.
  pubmed

• 11) Schaldon S, Deschodt G, Branger B, et al:Hemodialysis hypotention:the interleukin hypothesis restated. Proc. Eur. Dial. Trans Assoc 22; 229, 1985.

• 12) Horl WH, Schaefer RM, Heidland A:Effect of different dialyzers on proteinases and proteinase inhibitors during hemodialysis. Am J Nephrol 5:320, 1985.
  pubmed

• 13) Nguyen AT, Lethias C, Zingraff J, et al:Helnodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro with in microamounts of whole blood. Kidney Int 28; 158, 1985.
  pubmed

• 14) Floge J, Wilks MF, Granolleras C, et al:β2-microglobulin and dialysis-related amyloydosis. Contr. Nephrol 74; 120, 1989.

• 15) Himmelfarb J, Hakim RM:Biocompatibility and risk of infection in haemodialysis patients. Nephrol. Dial. Trans 9 (suppl. 2); 138, 1994.

• 16) van Ypersele C, Jadoul M, Malghem J, et al:Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. Kidrley Int 39; 1012, 1991.

• 17) Stiller S, Mann H, Brulmer H:Backfiltration in hemodialysis with highly permeable membrane. Contr Nephrol 46:23, 1985.

• 18) Hammer M, Kofoed-Johnsen J:The effects of increased dialysate sodium concentration on skeletal muscle and subcutaneous blood flow during hemodialysis. Contr Nephrol 79; 127,1990.

• 19) Swamy AP, Cestero ROM, Campbell RG, et al:Long-term effect of dialysate glucose on the lipid of maintenance hemodialysis patients. Trans Am Soc Artif Intern Organs 22; 54, 1976.

• 20) Novello A, Kelsch RC, Easterling RE:Acetate intolerance during hemodialysis. Clin Nephrol 5; 29, 1976.
  pubmed

• 21) Man NK, Itakura Y, Chauveau PH, et al:Acetate-free biofiltration:State of the art. Contr. Nephrol 108; 87, 1994.

• 22) Zucchelli P, Santoro A, Spongano M:Acetate-free biofiltration:Acidosis correction and cardiovascular stability. Contr Nephrol 108; 105, 1994.

• 23) Lindholln T, Thysell H, Yamamoto Y, et al:Temperature and vascular stability in hemodialysis. Nephron 39; 130, 1985.

• 24) Levy F:Improved left ventricular contractility with cool temperature hemodialysis. Kidney Int 41; 961, 1992.
  pubmed

• 25) Hegbrant J, Sternby J, Martensson L, et al:Possible prevention of hypoxemia by using cold hemodialysis (abstract). Blood Purif 11:190, 1993.

P.30 掲載の参考文献

• 1) Floge J, Granolleras C, Bingel M, et al:β2-microglobulin kinetics during hemodialysis and hemofiltration. Nephrol Dial Transplant 1:223, 1987.

• 2) 小林快三, 前田憲志, 他:血液透析患者に対する新しい体液管理法 (extracorporeal ultra-filtration method:ECUM) の開発と応用に関する研究. 日腎会誌 14:539, 1972.

• 3) Pillarella MR, Zydney AL:Analysis of solute clearance and flux in pre-and post-dilution hemofiltration. Trans Am Soc Artif Intern Oragans 34; 415, 1988.

• 4) David S, Cambi V:Hemofiltration; Predilution versus Postdilution. Contr Nephrol 96:77, 1992.

• 5) Quellhorst E, Rieger J, Scheler F, et al:Treatment of chronic uremia by an ultrafiltration Kidney:first clinical experience. Proc Eur Dial Transplant Assoc 13:314, 1976.

• 6) Shaldon S, Beau MC, Mion C, et al:Vascular stability during hemofiltration. Trans Am Soc Artif Intern Organs 26:391, 1980.
  pubmed

• 7) Baldamus CA, Ernst W, Frei U, et al:Sympathetic and hemodynamic response to volume removal during different forms of renal replacement therapy. Nephron 31:324, 1982.
  pubmed

• 8) Symposium on Hemofiltration J Dial 1:529, 1977.

• 9) Quellhorst EA, Schuenemann B, Mietzsch G:Long-term hemofiltration in 'poor risk' patients. Trans Am Soc Artif Intern Organs 33; 758, 1987.

• 10) Frei U, Koch KM:Fever and shock during hemofiltration. Contr Nephrol 36; 107, 1983.

P.38 掲載の参考文献

• 1) Usuda M, Shinzato T, Maeda K, et al:New simultaneous HF and HD with no infusion fluid. Trans. Am. Soc. Artif. Intern. Organs 28:24, 1982.
  pubmed

• 2) 前田憲志, 新里高弘, 小早川裕之:push and pull法. 臨床透析8 (3):51, 1992.

• 3) Shinzato T, Fujisawa K, Maeda k, et al:Newly developed economical and efficient push/ pull hemodiafiltration. Contr Nephrol 108:79, 1994.

• 4) Henderson LW, Beans E:Successful production of sterile pyrogen-free electrolyte solution by ultrafiltration. Kidney Int 14:522, 1978.
  pubmed

• 5) 小早川裕之, 新里高弘, 前田憲志, 他:Push/Pull HDFの安全性の検討. 腎と透析 27 (別冊):126, 1989.

• 6) 新里高弘, 前田憲志, 他:多数例に対するPush/Pull HDFの臨床応用. 人工臓器 16 (2):843, 1987.

• 7) 福島 純, 池崎定好, 松山家昌, 他:Push&Pull HDFの臨床経験-世話人施設の共同研究. 腎と透析 34 (3) (別冊):106, 1993.

• 8) Maeda K, Kobayakawa H, Fujita Y, et al:Effectiveness of Push/Pull hemodiafiltration using large-pore membrane for shoulder joint pain in long-term dialysis patients. Artif. Organs 14:321, 1990.
  pubmed

• 9) Shinzato T, Kobayakawa H, Maeda K:Comparison of various treatment modes in terms of β2-microglobulin removal.:Hemodialysis, Hemofiltration, and Push/Pull HDF. Artif. Organs 13:66, 1989.

• 10) Canaud B, Nguyen QV, Argiles A, et al:Hemodiafiltration using dialysate as substitution fluid. Artif Organs 11:188, 1987.
  pubmed

• 11) Rindi P, Pilone N, Cioni L, et al:Clinical experiment with a new hemodiafiltration (HDF) system. Trans Am Soc Artif Intern Organs 34:765, 1988.

• 12) Kerr PG, Argiles A, Flavier JL, et al:Comparison of hemodialysis and hemodiafiltration:Along-term longitudinal study. Kidney Int 41:1035, 1992.

P.40 掲載の参考文献

• 1) Wizemann V:Present clinical experience and future aspects of haemodiafiltration:in Cambi V (ed):Short Dialysis. Boston, Nijhoff, 293-320, 1987.

• 2) Sadler J:Quantity and quality of ESRD treatment in USA:in Klinkmann H Smeby L C (eds):Terminal renal failure:therapeutic problems, possibilities, and potentials. Contrib Nephrol 78:181-185, 1990.

• 3) Shaldon S:Short Haemodialysis. Contrib Nephrol 82:1-5, 1990.
  pubmed

• 4) Granger A, Vlchek D:An overview of the basic features of AN69 membrane. Proc. 1st Am. AN69 membrane scient. Exchange, 5-13, 1982.

• 5) Zucchelli P, Santoro A, Raggioto G, et al:Biofiltration in Uremia:Preliminary Obserbation. Blood purification 2:187-195, 1984.

• 6) 後藤 健, 岩本忠彦, 佐藤 卓, 他:Biofiltration with buffer free dialysate. 人工臓器 17 (1), 144-147, 1988.

• 7) Caravaca F, Pizarro JL, Arrobas M, et al:Hypersensitivity reactions related to acetate dialysate and cellulose acetate membrane. Nephron 45:158-159, 1987.
  pubmed

• 8) 吉山直樹, 桜井俊一朗:Biofiltration, 短時間透析. 日本臨牀 49 (増刊):332-336, 1991.

• 9) Kuno T, Kikuchi F, Yanai M, et al:Clinical Advantages of Acetate-Free Biofiltration. Contrib Nephrol 108:121-130, 1994.
  pubmed

• 10) 安藤亮一, 中川成之輔:血液浄化法とリン除去. 臨床透析 7:1473-1477, 1991.

P.50 掲載の参考文献

• 1) Kramer P, Wigger W, Rieger J, et al:Arteriovenous hemofiltration:A new and simple method for treatment of over-hydrated patients resistant to diuretics. Klin Wochenschr 55:1121-1122, 1977.
  pubmed

• 2) Bergstrom J, Asaba H, Furst P, et al:Dialysis, ultrafiltration, and blood pressure. Proc Eur Dial Trans Assoc 13:293-305, 1976.

• 3) Kramer P, Bohler J, Kehr A, et al:Intensive care potential of continuous arteriovenous hemofiltration. Trans Am Soc Artif Intern Organs 28:28-32, 1982.
  pubmed

• 4) Paganini EP, Nakamoto S:Continuous slow ultrafiltration in oliguric acute renal failure. Trans Am Soc Artif Intern Organs 23:201-204, 1980.

• 5) Kramer P, Kaufhold G, Grdne HJ, et al:Management of anuric intensive-care patients with arteriovenous hemofiltration. Int J Artif Organs 3:225-230, 1980.

• 6) Kaplan AA:Predilution versus postdilution for continuous arteriovenous hemofiltration. Trans Am Soc Artif Intern Organs 31:28-32, 1985.
  pubmed

• 7) Geronemus R, Schneider N:Continuous ateriovenous hemodialysis:A new modality for treatment of acute renal failuer. Trans Am Soc Artif Intern Organs 30:610-612, 1984.

• 8) Ronco C, Brendolan A, Bragantini L, et al:Arteriovenous hemodiafiltration associated with continuous arteriovenous hemofiltartion:acombined therapy for acute renal failure in the hypercatabolic patient. Blood Purif 5:33-40, 1987.

• 9) Van Geelen JA, Vincent HH, Schalekamp MADH:Continuous arteriovenous haemofiltration and haemodiafiltration in acute renal failure. Nephrol Dial Transplant 2:181-186, 1988.

• 10) Stiller S, Mann H, Byrne T:Continuous monitoring of blood volume during hemodialysis. Proc Eur Soc Artif Organs 7:167-171, 1980.

• 11) Keller F, Feldmann K, Abshagen U, et al:Diagnostic haemoperfusion for rapid detection of bactaeremia. Klin Wochenschr 59:425-429, 1981.

• 12) Lauer A, Saccaggi A, Ronco C, et al:Continuous arteriovenous hemofiltration in the critically ill patient:Clinical use and operational characteristics. Ann Intern Med 99:455-460, 1983.
  pubmed

• 13) Gotch FA, Keen ML:Precise control of minimal heparinization for high bleeding risk hemodialysis. Trans Am Soc Artif Intern Organs 23:168-175, 1977.
  pubmed

• 14) Kaplan AA, Petrillo R:Regional heparinization for continuous arterio-venous hemofiltration. Trans Am Soc Artif Intern Organs 33:312-315, 1987.

• 15) Pinnick RV, Wiegmann TB, Diederich DA:Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 308:258-261, 1983.
  pubmed

• 16) Toomasian JM, Hsu LC, Hirschl RB, et al:Evaluation of Duraflo II heparin coating in prolonged extracorporeal membrane oxygenation. Trans Am Soc Artif Intern Organs 34:410-414, 1988.

• 17) Arakawa M, Nagao M, Gejyo F, et al:Development of a new antithrombogenic continous ultrafiltration system. Artif Organs 15:171-179, 1991.

• 18) Olbricht C, Mueller C, Schurek HJ, et al:Treatment of acute renal failure in patients with multiple organ failure by continuous spontaneous hemofiltration. Trans Am Soc Artif Intern Organs 28:33-37, 1982.
  pubmed

• 19) Weiss L, Danielson BG, Wikstrom B, et al:Continuous arteriovenous hemofiltration in the treatment of 100 critically ill patients with acute renal failure:report on clinical outcome and nutritional aspects. Clin Nephrol 31:184-189, 1989.
  pubmed

• 20) Golper TA, Wedel SK, Kaplan AA, et al:Drug removal during continuous arteriovenous hemofiltration:theory and clinical obsevations. Int J Artif Organs 8:307-312, 1985.

• 21) Golper TA:Continuous arteriovenous hemofiltration in acute renal failure. Am J Kidney Dis 6:373-386, 1985.
  pubmed

P.56 掲載の参考文献

• 1) 日本透析療法学会統計調査委員会:わが国の慢性透析療法の現況 (1992年12月31日現在)

• 2) Maeda K, Shinzato T, Ota T, et al:Beta-2-microglobulin generation rate and clearance rate in maintenance hemodialysis patients. Nephron 56:118-125, 1990.
  pubmed

• 3) 前田憲志, 森田博之, 藤田芳郎, ほか:β2-ミクログロブリン (β2-MG)の除去よりみた持続治療の有用性, 腎と透析 別冊:27-31, 1990.

• 4) Gordon A, Popovtzer M, Greenbaum M, et al:Zirconium phosphate-a potentially useful adsorbent in the treatment of chronic uraemia. Proc Eur Dial Transplant Assoc 5:86-94, 1969.

• 5) Gordon A, Better OS, Greenbaum MA, et al:Clinical maintenance hemodialysis with a sorbent-based, low-volume dialysate regeneration system. Tran Am Soc Artif Intern Organs 17:253-256, 1971.

• 6) Mourad G, Issautier R, Mion C:Aportable hemodialysis system with sorbent regeneration of dialysate:preliminary results. Tran Am Soc Artif Intern Organs 31:568-571, 1985.

• 7) 土肥健純, 村上 元, 堀内 孝, ほか:携帯型人工腎臓の開発, 人工臓器7:962-965, 1978.

• 8) 阿岸鉄三, 江良和雄, 金子岩和, ほか:携行式人工腎臓の臨床, 人工臓器 10:48-51, 1981.

• 9) 土肥健純, 大坪 修, 瀬尾真一, ほか:携帯型plamsa exchange-hemofiltration装置の開発, 人工臓器 8:561-564, 1979.

• 10) Kolff WJ, Jacobsen S, Stephen RL, et al:Towards a wearable artificial kidney. Kidney Int 10:S-300-304, 1976.

• 11) 瀬尾真一, 大坪 修, 渡辺俊文, ほか:装着型人工腎臓装置-小型血液ポンプの開発-, 人工臓器11:48-51, 1982.

• 12) 江良和雄, 阿岸鉄三, 会田和雄, ほか:Jacket type (JAK-1) 人工腎の試作, 人工臓器 7:253-255, 1978.

• 13) Henderson LW, Parker HR, Schroeder JP, et al:Continuous low flow hemofiltration with sorbent regeneration of ultrafiltrate. Trans Am Soc Artif Intern Organs 24:178-184, 1978.
  pubmed

• 14) Tada Y, Horiuchi T, Ohta Y, et al:A new approach for the filtrate regeneration system in the wearable artificial kidney. Artif Organs 14 (6):405-409, 1990.
  pubmed

• 15) Murisasco A, Reynier Jp, Ragon A, et al:Continuous arterio-venous hemofiltration in a wearable device to treat end-stage renal disease. Trans Am Soc Artif Intern Organs 32:567-571, 1986.

• 16) Shaldon S, Beau MC, Deschodt G, et al:Continuous ambulatory hemofiltration. Trans Am Soc Artif Intern Organs 26:210-212, 1980.
  pubmed

• 17) Takai I, Shinzato T, Morita H, et al:A new treatment strategy using both intermittent short dialysis and continuous ambulatory hemofiltration. Trans Am Soc Artif Intern Organs 37:325-327, 1991.

• 18) 高井一郎, 新里高弘, 中井 滋, ほか:短時間透析と装着型人工腎臓の組み合わせによる連続治療, 透析会誌 25:901-905, 1992.

P.64 掲載の参考文献

• 1) 日本透析療法学会統計調査委員会:わが国の慢性透析療法の現況 (1992年12月31日現在)

• 2) Cambi V, Arisi L, Buzio C, et al:Intensive utilisation of a dialysis unit. Proc Eur Dial Transplant Assoc 10:342-346, 1973.
  pubmed

• 3) Lowrie EG, Laird NM, Parker TF, et al:Effect of the hemodialysis prescription on patient morbidity-report from the National Cooperative Dialysis Study. N Engl J Med 305:1176-1181, 1981.
  pubmed

• 4) Gotch FA, Sargent JA:A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 28:526-534, 1985.
  pubmed

• 5) Keshaviah P, Luehmann D, Ilstrup K, et al:Technical requirements for rapid high efficiency therapies. Artif Organs 10 (3):189-194, 1986.
  pubmed

• 6) Keshaviah P, Collins A:Rapid high-efficiency bicarbonate hemodialysis. Trans Am Soc Artif Intern Organs 32:17-23, 1986.

• 7) Collins A, Ilstrup K, Hanson G, et al:Rapid high-efficiency hemodialysis. Artif Organs 10 (3):185-188, 1986.
  pubmed

• 8) Kramer P, Broyer M, Brunner FP, et al:Combined report on regular dialysis and transplantation in Europe, XII, 1981 Proc Eur Dial Transplant Assoc 19:4-59, 1982.

• 9) Kjellstrand CM:Short dialysis increases morbidity and mortality. Contr Nephrol 44:65-77, Karger, Basel, 1985.

• 10) Sadler J:Quantity and quality of ESRD treatment in the United States of America. Contr Nephrol 78:181-185, Karger, Basel, 1990.

• 11) Lowrie EG, Lew NL:Death risk in hemodialysis patients:The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 (5):458-482, 1990.
  pubmed

• 12) Held PJ, Levin NW, Bovbjerg RR, et al:Mortality and duration of hemodialysis treatment. JAMA 265 (7):871-875, 1991.
  pubmed

• 13) Sargent JA:Shortfalls in the delivery of dialysis. Am J Kid Dis 15 (5):500-510, 1990.
  pubmed

• 14) Shinaberger JH, Miller JH, Gardner PW:Short treatment. Chapter 16.In:Replacement of renal function by dialysis, 3rd ed. (ed. by Maher JF), 360-381, Dordrecht, Kluwer, 1989.

• 15) Gotch FA, Yarian S, Keen M:Akinetic survey of US hemodialysis prescriptions. Am J Kid Dis 15 (5):511-515, 1990.

• 16) Babb AL, Strand MJ, Uvelli DA, et al:Quantitative description of dialysis treatment; adialysis index. Kidney Int 2 (suppl 2):S 23-29, 1975.

• 17) Man NK, Cuille G, Zingraff J, et al:Evaluation of plasma neurotoxin concentration in uraemic polyneuropathic patients. Proc Eur Dial Trans Assoc 15:154-170, 1978.

• 18) Maeda K, Shinzato T, Ota T, et al:Beta-2-microglobulin generation rate and clearance rate in maintenance hemodilalysis patients. Nephron 56:118-125, 1990.

• 19) 前田憲志, 森田博之, 藤田芳郎, ほか:β2ミクログロブリン (β2-MG) の除去よりみた持続治療の有用性, 腎と透析 別冊:27-31, 1990.

• 20) Sugisaki H, Onohara M, Kunitomo T:Phospate in dialysis patients. Trans Am Soc Artif Intern Organs 29:38-43, 1983.

• 21) Shinaberger JH, Miller JH, von Albertini B, et al:Phospate removal by conventional dialysis, high efficiency dialysis and high flux hemodiafiltration. Kidney Int 31:245, 1987.

• 22) Mahida BH, Dumler F, Zasuwa G, et al:Effect of cooled dialysate on serum cate cholamines and blood pressure stability. Trans Am Soc Artif Intern Organs 29:384-388, 1983.

• 23) Shaldon S, Beau MC, Deschodt G, et al:Vascular stability during hemofiltration. Trans Am Soc Artif Intern Organs 26:391-393, 1980.
  pubmed

• 24) Lonnemann G, Bingel M, Floege J, et al:Detection of endotoxin-like interleukin-1-inducing activity during in vitro dialysis. Kidney Int 33:29-35, 1988.
  pubmed

• 25) Shaldon S, Beau MC, Deschodt G, et al:Mixed hemofiltration (MHF):18 months experience with ultrashort treatment time. Trans Am Soc Artif Intern Organs 27:610-612, 1981.
  pubmed

• 26) Keshaviah P, Berkseth R, Ilstrup K, et al:Reduced treatment time:Hemodialysis (HD) versus hemofiltration (HF). Trans Am Soc Artif Intern Organs 31:176-180, 1985.
  pubmed

• 27) Ota K, Suzuki T, Ozaku Y, et al:Short-time hemodiafiltration using polymethylmethacrylate hemodiafilter. Trans Am Soc Artif Intern Organs 24:454-457, 1978.
  pubmed

• 28) Albertini VB, Miller JH, Gardner PW, et al:High-flux hemodiafiltration:under six hours/week treatment. Trans Am Soc Artif Intern Organs 30:227-231, 1984.

• 29) Usuda M, Shinzato T, Sezaki R, et al:New simultaneous HF and HD with no infusion fluid. Trans Am Soc Artif Intern Organs 28:24-27, 1982.
  pubmed

• 30) Shinzato T, Maeda K, Tsuruta Y, et al:Clinical application of push/pull HDF. Progress in Artificial Organs-1985, edited by Y. Nose, C. Kjellstrand and P. Ivanovich, ISAO Press, Cleveland, 1986.

• 31) 前田憲志, 新里高弘:Push/Pull HDFの短時間化の限界. 人工臓器15 (1):125-128, 1986.

• 32) Maeda K, Shinzato T, Kobayakawa H:Effects of L-carnitine administration on shortchain fatty acid (acetic acid) and long-chain fatty acid metabolism during hemodialysis. Nephron 51 (3):355-361, 1989.
  pubmed

• 33) Henderson LW, Sanfellippo ML, Beans E:"On-line" preparation of sterile pyrogen-free electrolyte solution. Trans Am Soc Artif Intern Organs 24:465-467, 1978.
  pubmed

• 34) Miller JH, von Albertini B, Gardner PW, et al:Technical aspects of high-flux hemodiafiltration for adequate short (under 2 hours) treatment. Trans Am Soc Artif Inter Organs 30:377-381, 1984.

• 35) Zucchelli P, Santoro A, Raggiotto G, et al:Biofiltration in uremia:preliminary observations. Blood Purif 2:187-195, 1984.

• 36) Bene B, Beruard M, Perrone B, et al:Simultaneous dialysis and filtration with bufferfree dialysate. Blood Purif 2:217, 1985.

• 37) Man NK, Ciancioni C, Perrone B, et al:Renal biofiltrataion. Trans Am Soc Artif Intern Organs 35:8-13, 1989.

• 38) Zucchelli P, Santoro A, Ferrari G, et al:Acetate-free biofiltration:hemodiafiltration with base-free dialysate. Blood Purif 8:14-22, 1990.
  pubmed

P.72 掲載の参考文献

• 1) 日本透析療法学会統計調査委員会:わが国の慢性透析療法の現況 (1992年現在). 透析会誌 27:1-20, 1994.

• 2) 斎藤明, 横井由美:家庭透析. 日本臨牀 (増刊号) 50:1023-1027, 1992.

• 3) Robert A, Gutman, Michael J, Blumenkrantz. Frederick K, et al:Controlled comparison of hemodialysis and peritoneal dialysis:Veterans administration multicenter study. Kidney Int 26:459-470, 1984.

• 4) William J. Johnson, Stephen B. Kurtz, William M. O'Fallon, et al:Results of treatment of renal failure by means of home hemodialysis. Mayo Clin Proc 59:663-668, 1984.

• 5) 川口良人, 久保仁, 若林良則, ほか:Continuous ambulatory peritoneal dialysis (CAPD) における最近の進歩と問題点. 透析会誌 25:507-515, 1992.

• 6) Lional U. Mailloux, Alessandro G. Bellucci, Peter A. Bluestone, et al:Predictors of survival in patients undergoing dialysis. Am J Med 84:855-862, 1988.

• 7) Barbara G. Delano, Eli A. Friedman:Correlates of decade-long technique survival on home hemodialysis. ASAIO Trans 36:M 337-M 339, 1990.

• 8) Roger W. Evans, Diane L. Manninen, Edmund G. Lowrie, et al:The quality of life of patients with end-stage renal disease. N Engl J Med 312:553-559, 1985.

• 9) Philip LP Morris, Bernard Jones:Life satisfaction across treatment methods for patients with end-stage renal failure. Med J Aust 150:428-432, 1989.

• 10) Nolph KD:Overview of peritoneal dialysis. Twelfth annual conference on peritoneal dialysis (abstract). Seattle, USA, 1992.

• 11) Raine AEG, Margreiter R, Valderrabano F, et al:Report on management of renal failure in Europe, XXII, 1991.Nephrol Dial Transplant Suppl 2:7-35, 1992.

P.81 掲載の参考文献

• 1) Heinrich D, Gorg T, Schulz M:Effects of unfractionated and fractionated heparins on platelet function. Haemostasis 18 (Suppl 3):48, 1988.

• 2) Lindsay RM, Rourke JTB, Edwards RO:The role of heparin on platelet retention by acrylonitrile co-polymer dialysis membranes. J Lab Clin Med 89:4, 1977.

• 3) King DJ, Kelton JG:Heparin-associated thrombocytopenia. Ann intern med 100:535, 1984.
  pubmed

• 4) Holmer E, Kurachi K, Sderstrom G:The molecular weight dependency of the rate enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 193:395, 1981.

• 5) Jordan RE, Oosta GM, Gardner WT, et al:The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol chem 255; 10081, 1980.
  pubmed

• 6) Lane DA, Denton J, Flynn AM, et al:Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.Biochem J 218; 725, 1984.
  pubmed

• 7) Danielsson A, Raub E, Lindahl U, et al:Role of ternary complexes in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 261; 15467, 1986.
  pubmed

• 8) Henny CP, Ten Cate H, Van Bronswijk H, et al:Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1:890, 1983.
  pubmed

• 9) 太田和夫, 鈴木利昭, 越川昭三, 他:出血性病変を有する血液透析患者における低分子ヘパリンFR-860の臨床評価-ヘパリンを対照とした多施設共同比較臨床試験. 診療と新薬 27, 33:1990.

• 10) Schrader J, Stibbe W, Armstrong VW, et al:Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 33:890, 1988.
  pubmed

• 11) Shcmitt Y, Schneider H:Low-molecular-weight heparin (LMWH):influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 8; 438, 1993.

• 12) Gouault-Heilmann M, Huet Y, Adnot S, et al:Low molecular weight heparin fractions as alternative therapy in heparin-induced thrombocytopenia. Haemostasis 17:134, 1987.
  pubmed

• 13) Suzuki T, Ota K, Naganuma S, et al:Clinical application of Fragmin (FR-860) in hemodialysis:Multicenter cooperative study in Japan. Semin Thromb Hemostasis 16 (Suppl):46, 1990.

• 14) 越川昭三, 秋沢忠男, 太田和夫, 他:FUT-175の血液透析用局所抗凝固薬としての臨床評価-多施設共同研究. 透析会誌 20:951, 1987.

• 15) 越川昭三, 秋沢忠男, 関口 孝, 他:FUT-175の血液透析用抗凝固薬としての有用性について-多施設共同研究. 薬理と治療 16:171, 1988.

• 16) 秋沢忠男, 越川昭三, 岩本里美, 他:血液透析における透析用抗凝固薬 FUT-175およびその 代謝産物の動態. 腎と透析 2 6:947, 1989.

• 17) Holmer E, Soderberg K:Inhibition of heparin oligosaccharides by protamin chloride. Semin Thromb Hemostasis 11:241, 1985.

• 18) Glaser P, Guedsder R, Eurin VB, et al:Hemodialysis without heparin is possible. Lancet 1:579, 1979.

• 19) Sreedhara R, Himmelfarb J, Lazarus JM, et al:Anti-platelet therapy in graft thrombosis; results of a prospective, randomized, double-blind study. Kidney Int 45:1477, 1994.
  pubmed

P.89 掲載の参考文献

• 1) Comty C, Luchmann D, Wathen, et al:Prescription water for chronic hemodialysis. Trans Am Soc Artif Intern Organs 20:189, 1974.

• 2) Klinkman H, Falkenhagen D, Smollich BP:Investigation of the permeability of highly permeable polysulfone membranes for pyrogens. Contr Nephrol 46; 174-183, 1985.

• 3) Stiller S, Mann H, Brunner H:Backfiltration in hemodialysis with highly permeable membranes. Corltr Nephrol 46; 23-32, 1985.
  pubmed

• 4) Ebben JP, Hirsch DN, Luehmann DA, et al:Microbiologic contamination of liquid bicarbonate concentrate for hemodialysis. Trans Am Soc Artif Intern Organs 33:269-273, 1987.

• 5) Takahashi I, Shimizu A, Aoki M, et al:Structural requirements of endotoxic lipopolysaccharides and bacterial cell walls in induction of interleukin-1.Blood Purif 6:188-206, 1988.

• 6) 中野昌康:エンドトキシン研究の進歩. 感染・炎症・免疫 18:239-249, 1988.

• 7) Dinarello CA:Cytokines and biocompatibility. Blood Purif 8:208-213, 1990,
  pubmed

• 8) Schaldon S, Deschodt G, Branger B, et al:Hemodialysis hypotension:the interleukin hypothesis restated. Proc Eur Dial Transplant Assoc 22:229-243, 1985.

• 9) Dinarello CA, Koch KM, Schaldon S:Interleukin 1 and its relevance in patients treated with hemodialysis. Kidney Int 33:S 21-26, 1988.

• 10) Morita T, Tanaka S, Nakamura T, et al:Anew (1→3)-β-D-glucan-mediated coagulation pathway found in limulus amebocytes. FEBS Lett., 129:318-321, 1981.

• 11) 山上征二, 清田敦彦, 杉村武嗣, 他:透析施行時のエンドトキシン (ET) 動態-新しいET測定法による検討. 腎と透析1992年別冊ハイパフォーマンス・メンブレン'92 1992.

• 12) Lonneman G, Bingel M, Floege J, et al:Detection of endotoxin like interleukin-1 inducing activity during in vitro dialysis. Kidney Int 33:29-35, 1988.

• 13) Yamagami S, Adachi T, Sugimura T, et al:Detection of endotoxin antibody in longterm dialysis patients. Int J Artif Organs 4:205-210, 1990.
  pubmed

• 14) 安島慶朗, 関口俊之, 掛札祐司, 他:透析液中エンドトキシン検索と除去の試み. 透析療法学会雑誌 22; 448, 1989.

P.95 掲載の参考文献

• 1) Schmidt M, Baldamas CA, Schoeppe W:Backfiltration in hemodialysers with highly permeable membranes. An in vitro and in vivo investigation. Bllod Purif 2:108-114, 1984.

• 2) Hosoya N, Sakai K:Backdiffusion rather than backfiltration enhances endotoxin transport through highly permeable dialysis membrane. Trans Am Soc Artif Intern Organs 36:311-313, 1990.

• 3) 日本透析医学会透析調査委員会:わが国の慢性透析療法の現況. 1993.

• 4) Gejyo F, Odani S, Yamada T, et al:β2-microglobulin:A new form of amyloid protein associated with chronic hemodialysis. Kidney Int 30:385-390, 1986

• 5) Babb AL, Poporich RP, Christopher TG, et al:The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Int Organs 17:81, 1971.

• 6) Floege J, Bartsch A, Schulze M, et al:Clearance and synthesis rates of β2-microglobulin in patients undergoing hemodialysis and in normal subjects, J Lab Clinic Med 118:153-165, 1991.

• 7) 岸本武利:透析液とエンドトキシン, Clinical Engineering 4:31-38, 1993.

• 8) Curtis JR, Wing AJ, Coleman JC:Bacillus cereus bacteremia:a complication of imtermittent hemodialysis, Lancet 1:136-138, 1967.

• 9) Henderson LW, Kock KM, Dianarello CA, et al:Hemodialysis hypotension:The Interleukin hypothsis, Blood Purif 1:3-8, 1983.

• 10) 前田憲志, 新里高弘:血液濾過透析における補充液の量と質, Clinical Engineering 4:15-20.1993.

• 11) 酒井清孝, 峰島三千男, 竹澤真吾, ほか:透析スタッフのための血液浄化の基礎. IPC 1989

• 12) 金子岩和, 阿岸鉄三, 山形桂仁, ほか:中空糸型透析器の基礎的設計に関する考察. 人工臓器 7:645, 1978.

• 13) Stiller S, Mann H, Brunner H:Backfiltration in hemodialysis with highly permeable membrane, Contr Nephrol 46:23-32, 1985.

• 14) Klinkmann H, Falkenhaugen D, Smollich BP:Investigation of the permeability of highly permeable polysulfone membranes for pyrogens. Contr Nephrol 46:174-183, 1985.

• 15) Ronco C:Backfiltration, Int J Artif Organs 34:594, 1988.

• 16) Baurmeister U, Vienken J, Daum V:High-flux dialysis membranes, endotoxin transfer by backfiltration can be a problem. Nephrol Dial Transplant 4:89, 1989.

• 17) Ronco C:Backfiltration in clinical dialysis:nature of the phenomenon, mechanisms and possible solutions. Int J Artif Organs 13:11-21, 1990.
  pubmed

• 18) 吉見靖男, 酒井清孝:血液透析における逆濾過. Clinical Engineering 4:21-30, 1993.

• 19) 細矢範行, 酒井清孝:HP透析器における逆濾過の抑制を目的とした透析器至適設計の検討. 人工臓器 20:42-47, 1991.

• 20) 細矢範行, 酒井清孝:逆濾過現象. Clinical Engineering 1:454-459, 1990.

• 21) 細矢範行, 酒井清孝:逆拡散・逆濾過によるエンドトキシン輸送の検討. 腎と透析別冊 45-48, 1990.

• 22) Usuda M, Shinzato T, Maeda K, et al:New simultaneous HF and HD with no infusion fluid. Trans Am Soc Artif Intern Organs 28:24-27, 1982.
  pubmed

• 23) Shinzato T, Fujisawa K, Maeda K, et al:Newly developed economical and efficint push/ pull hemodaifiltration. Contrib Nephrol 108:79-86, 1994.

• 24) 新里高弘, 他:Protein permeable membraneをいたpush/pull HDFのアルブミン喪失抑制効果. ハイパフォーマンスメンブレン 腎と透析:32-35, 1994.

P.101 掲載の参考文献

• 1) Brennan DC, Jevnikar AM, Takei F, et al:Mesangial cell accessory functions:Mediation by intercellular adhesion molecule-1.Kid Intern 38 (6):1039-46, 1990.

• 2) Adler S, Baker PJ, Johnson RJ, et al:Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J Clin Invest 77 (3):762-7, 1986.
  pubmed

• 3) Lovett DH, Haensch GM, Goppelt M, et al:Activation of glomerular mesangial cells by the terminal membrane attack complex of complement. J Immunol 138 (8):2473-80, 1987.
  pubmed

• 4) Halperin JA, Taratuska A, Nicholson-Weller A:Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 91 (5):1974-8, 1993.
  pubmed

• 5) Miyata T, Inagi R, Hong K, et al:Fluid-phase activation of the alternative pathway of complement by excess factor D in regularly dialyzed patients. Nephron 60 (2):144-9, 1992.
  pubmed

• 6) Pascual M, Paccaud JP, Macon K, et al:Complement activation by the alternative pathway is modified in renal failure:the role of factor D. Clin Nephrol 32:185-93, 1989.
  pubmed

• 7) Pangburn MK, Muller-Eberhard HJ:The alternative pathway of complement Springer Semin Immunopathol 7:163-192, 1984.
  pubmed

• 8) Ivanovich P, Chenoweth DE, Schmidt R, et al:Symptoms and activation of granulocytes and complement with two dialysis membranes. Kid Intern 24:758-63, 1983.

• 9) Chenoweth DE:Complement activation during hemodialysis:Clinical observatiorls, proposed mechanisms, and theoretical implications. Artif Organs 8:281-7, 1984.comparative study. Nephrol Dial Transplant 6 supple 2:55-8, 1991.

• 11) Chenoweth DE, Cheung AK, Ward DM, et al:Anaphylatoxin formation during hemo dialysis:Comparison of new and re-used dialyzers. Kidney Int 24:770-4, 1983.

• 12) Hakim RM, Lowrie EG:Effect of dialyzer reuse on leukopenia, hypoxemia and total hemolytic complement system. Trans Am Soc Artif Intern Organs 26:159-64, 1980.
  pubmed

• 13) Cheung AK, Parker CJ, Janatova J, et al:Modulation of complement activation on hemodialysis membranes by immobilized heparin. J Am Soc Neohrol 2 (8):1328-37, 1992.
  pubmed

• 14) Lesavre PH, Muller-Eberhard HJ:Mechanism of action of factor D of the alternative complement pathway. J Exp Med 148:1498-509, 1978.
  pubmed

• 15) Volanakis JE, Schrohenloher RE, Stround RM:Human factor D of the alternative complement pathway:Purification and characterization. J Immunol 119:337-42, 1977.

• 16) Barnum SR, Niemann MA, Kearney JF, et al:Quantitation of complement factor D in human serum by a solid-phase radioimmunoassey. J Immun Meth 67:303-9, 1984.

• 17) Volanakis JE, Barnum SR, Giddens M et al:Renal filtration and catabolism of complement protein D. N Eng J Med 312:395-9, 1985.

• 18) Miyata T, Oda O, Inagi R, et al:Moleculer and functional identification and purufication of complement factor D from urine of patients with chronic renal failure. Mol Immunol 27 (7):637-44, 1990.

• 19) Miyama A, Kato T, Horai S, et al:Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I.Generation of the activated complex. Biken J 18:193-204, 1975.
  pubmed

• 20) Kobayakawa H, Miyata T, Inagi R, et al:Effects of excess factor D on early-and late-phase activation of the complement cascade. Nippon Jinzo Gakkai Shi 34 (1):103-6, 1992.
  pubmed

• 21) Inagi R, Miyata T, Hong K, et al:Decreased activity of complement-mediated immune complex clearance in hemodialysis patients. Clin Immunol Immunopathol 68 (3):333-9, 1993.
  pubmed

• 22) Pascual M, Schifferli JA:Adsorption of complement factor D by polyacrylonitrile dialysis membranes. Kidney Int 43 (4):903-11, 1993.
  pubmed

• 23) Inagi R, Miyata T, Maeda K, et al:FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a. Immunol Lett 27 (1):49-52, 1991.
  pubmed

• 24) Inagi R, Miyata T, Oda O, et al:Evaluation of proteolytic activity of factor D accumulated as an active serine protease in patients with chronic renal failure. Nephron 66 (3):285-90, 1994.
  pubmed

P.118 掲載の参考文献

• 1) Quinton WE, Dillard DH, Scribner BH:Cannulation of blood vessels for prolonged hemodialysis. Trans Am Soc Artif Intern Organs 6:104, 1960.

• 2) Shaldon S, Chiandussi L, Higgs B:Hemodialysis by percutaneous catheterization of the femoral artery and vein with regional heparinization. Lancet 2:857, 1961.

• 3) Shaldon S, Silva H, Pomeroy J, et al:Percutaneous femoral venous catheterization and reusable dialyzers in the treatment of acute renal failure. Trans Am Soc Artif Intern Organs 10:133, 1964.
  pubmed

• 4) Brescia MJ, Cimino JE, Appel K, et al:Chronic hemodialysis using ven ipuncture and a surgically created arteriovenous fistula. N Engl J Med 275:1089, 1966.

• 5) Whittemore AD:Vascular access for hemodialysis, in Surgical Care of the Patient with Renal Failure, edited by Tilney NL, Lazarus JM, Philadelphia, WB Saunders Co., p 49, 1982.

• 6) Tilney NL, Whittemore AD:Dialysis access in difficult patients, in Vascular Surgery, edited by Bell PRF, Tilney NL, London, Butterworths, p 175, 1984.

• 7) Bossell JA, Abbott JA, Lim RC:A radial steal syndrome with arteriovenous fistula for hemodialysis. Ann Intern Med 75:387, 1971.

• 8) May J, Tiller D, Johnson J, et al:Saphenous vein arteriovenous fistula in regular dialysis treatment:N Engl J Med 280:770, 1969.
  pubmed

• 9) Wedgewood KR, Wiggins PA, Guillou PJ:A prospective study of end-to-side vs side-to-side arteriovenous fistulas for haemodialysis. Br J Surg 71:540, 1984.

• 10) Buselmeier TJ, Simmons RL, Najarian JS, et al:The clinical aplication of a new prosthetic arteriovenous shunt. Nephron 12:22, 1973.

• 11) Thomas TI:Large vessel applique arteriovenous shunt for hemodialysis:Anew concept. Am J Surg 120:244, 1970.

• 12) Munda R, First MR, Alexander JW, et al:Polytetrafluoroethylene graft survival in hemodialysis. JAMA 249:219, 1983.
  pubmed

• 13) Ishihara AM, Myers CH:Longevity of arteriovenous shunts for dialysis. Ann Surg 168:281, 1968.
  pubmed

• 14) Foran RF, Golding AL, Treiman RL, et al:Quinton-Scribner cannulas for hemodialysis:Review of four years:experience. Calif Med 112:8, 1970.
  pubmed

• 15) Morgan AP, Dammin GJ, Lazarus JM:Failure modes in secondary vascular access for hemodialysis. ASAIO J 1:44, 1978.

• 16) Rosenthal JJ, Spigelman A, Gaspar MR, et al:Problem with bovine heterografts for hemodialysis. Am J Surg 130:182, 1975.

• 17) Johnson JM, Kenoyer MR, Johnson KE, et al:The modified bovine heterograft in vascular access for chronic hemodialysis. Ann Surg 183:62, 1976.
  pubmed

• 18) Hurt AV, Batello-Cruz M, Skipper BJ, et al:Bovine carotid artery heterograft versus polytetra-fluoroethylene grafts. Am J Surg 146:844, 1983.

• 19) Jenkins AM, Buist TA, Glover SD:Medium-term follow-up of forty autogenous vein and forty polytetrafluoro-ethylene (Gortex) grafts for vascular access. Surgery 88:667, 1980.

• 20) Palder SB, Kirkman RL, Whittemore AD, et al:Vascular access for hemodialysis. Ann Surg 202:235, 1985.
  pubmed

• 21) Whittemore AD:Vascular access for hemodialysis, in surgical care of the patient with renal failure, edited by Tilney NL, Lazarus JM, Philadelphia, WB Saunders Co., p 59, 1982.

• 22) Selman SH, Rhodes RS, Anderson JM, et al:Atheromatous changes in expanded polytetrafluoro-ethylene grafts. Surgery 87:630, 1980.

P.123 掲載の参考文献

• 1) 東側和発, 利見和夫, 坂下恵一郎, 他:腎臓 14(1):57-62, 1991.

• 2) 出口克巳, 白川 哉:血液と脈管 15:14 25, 1984.

• 3) Weiss HJ:Von Willebrand factor and platelet function. Ann NY Acad Sci 614:125-137, 1991.
  pubmed

• 4) Stern DM, Esposito C, Gerlach H, et al:Endothelium and regulation of coagulation. Diabetes Care 14:160-166, 1991.
  pubmed

• 5) Esmon CT, Johnson AE, Esmon NL, et al:Initiation of the protein C pathway. Ann NY Acad Sci 614:30-43, 1991.
  pubmed

• 6) Ross R, et al:The pathogenesis of atherosclerosis. N Eng J Med 314:488-500, 1986.

P.128 掲載の参考文献

• 1) Vanholder R, Dell:Aquila R, Ringoir S:Phagocyte function in uremia. Adv Exp Med Biol 297:193-205, 1991.
  pubmed

• 2) Rosenthal SR:Uremic dermatitis. Arch Dermatol Syphilol 23:934-945, 1931.

• 3) Olmstead EG, Lunseth JH:Skin manifestations of chronic acidosis. Arch Dermatol 77:304-313, 1958.

• 4) Cawley EP, Hoch-Ligeti C, Bond GM:The eccrine sweat glands of patients in uremia. Arch Dermatol 84:889-897, 1961.

• 5) Goldblum SE, Reed WP, Ulrich JA, et al:Staphylococcal carriage and infections in hemodialysis patients. Dial Transplan 7:1140-1163, 1978.

• 6) Kirmani N, Tuazon CU, Murray HW, et al:Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 138:1675-1679, 1978.

• 7) Nayman J:Effect of renal failure on wound healing in dogs:response to hemodialysis following uremia induced by uranium nitrate. Ann Surg 164:277-235, 1966.

• 8) Balch HH, Evans JR:The influence of acute renal failure on resistance to in fection:an experimental study. Ann Surg 144:191-197, 1956.

• 9) Buchanan WW, Klinenberg JR, Seegmiller JE:The inflammatory response to injected microcrystalline monosodiun urate in normal, hyperuricemic, gouty and uremic subjects. Arthritis Rheum 8:361-367, 1965.
  pubmed

• 10) MacGregor RR:Granulocyte adherence changes induced by hemodialysis, endotoxin, epinephrine, and glucocorticoids. Ann Intern Med 86:35-39, 1977.

• 11) Siriwatratananonta P, Sinsakul V, Stern K, et al:Defective chemotaxis in uremia. J Lab Clin Med 92:402-407, 1978.
  pubmed

• 12) Goldblum SE, Van Epps DE, Reed WP:Serum inhibitor of C5 fragment-mediated polymorphonuclear leukocyte chemotaxis associated with chronic hemodialysis. J Clin Invest 64:255-264, 1979.
  pubmed

• 13) Vanholder R, Ringoir S:Polymorphonuclear cell function and infection in dialysis. Kidney Int 42:S-91-S-95, 1992.

• 14) Veys N, Vanholder R, Ringoir S:Correlation of deficient phagocytosis during eryth-ropoietin treatment in maintenance hemodialysis patients. Am J Kidney Dis 19:358-363, 1992.

• 15) Flament J, Goldman M, Waterlot Y, et al:Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 25:227-230, 1986.
  pubmed

• 16) Boelaert JR, Cantinieaux BF, Hariga CF, et al:Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 5:504-507, 1990.
  pubmed

• 17) Keane WF, Shapiro FL, Rij L:Incidence and type of infections occuring in 445 chronic hemodialysis patients. Trans Am Soc Artif Intern Organs 23:41-47, 1977.

• 18) Keane WF, Maddy MF:Host defenses and infectious complications in maintenance hemodialysis patients, in Replacement of Renal Function by Dialysis, edited by Maher JF, Dordrecht, Kluwer Academic, pp. 865-880, 1989.

P.132 掲載の参考文献

• 1) 阿岸鉄三, 金子岩和, 太田和夫:血液透析用血液出入口としての動脈化静脈の内圧と動脈圧の 相関性について. 人工臓器7:587-592, 1978.

• 2) 山海嘉之, 太田道男, 太宰利博, ほか:透析中のシャント部血圧の連続計測法. 日本透析療法 学会雑誌24:327-331, 1991.

• 3) Nakane K, Shinzato T, Maeda K:Continuous measurement of pressure in internal arteriovenous fistulae and prevention of symptomatic hypotension during hemodialysis. ASAIO Transactions Volume 37:232-234, 1991.

• 4) 幾高敏晴, 石黒源之, 島袋盛-, ほか:Shunt内圧連続モニタリングカテーテルの開発とその 臨床応用 (第1報). 日本透析療法学会雑誌26:1131-1135, 1993.

• 5) Shinzato T, Nakai S, Takai I, et al:A new wearable system for continuous monitoring of arteriovenous fistulae. ASAIO Journal 39:137-140, 1993.
  pubmed

P.141 掲載の参考文献

• 1) Maeda K, Fujita Y, Shinzato T, et al:Mechanism of dialysis-induced hypotension. Trans Am Soc Artif Intern Organs 35:245-247, 1989.

• 2) Azancot I, Degoulet P, Juillet Y, et al:Hemodynamic evaluation of hypotension during chronic hemodialysis. Clin Nephrol 8:312-316, 1977.
  pubmed

• 3) Maeda K, Morita H, Shinzato T, et al:Role of hypovolemia in dialysis-induced hypotension. Artif Organs 12:116-121, 1988.
  pubmed

• 4) Shinzato T, Nakai S, Odani H, et al:Relationship between dialysis-induced hypotension and adenosine released by ischemic tissue. Trans Am Soc Artif Intern Organs 38:M 286-M 290, 1992.

• 5) Shinzato T, Miwa M, Nakai S, et al:Role of adenosine in dialysis-induced hypotension. J Am Soc Nephrol 4:1987-1994, 1994.
  pubmed

• 6) Berne RM, Levy MN:Special Circulations, in Physiology (3rd ed.), edited by Berne RM, Levy MN, Missouri, Mosby Year Book, pp 510-531, 1992.

• 7) Rubio R, Wiedmeier VT, Berne RM:Nucleoside phosphorylase:localization and role in the myocardial distribution of purines. Am J Physiol 222:550-555, 1972.

• 8) Imai S, Riley A, Berne RM:Effect of ischemia on adenine nucleotides in cardiac and skeletal muscle. Circ Res 15:443-450, 1964.
  pubmed

• 9) Herlihy JT, Bockman EL, Berne RM, et al:Adenosine relaxation of isolated vascular smooth muscle. Am J Physiol 230:1239-1243, 1976.
  pubmed

• 10) Schnaar RL, Sparks HV:Response of large and small coronaryarteries to nitroglycerin, NaNO2, and adenosine. Am J Physiol 223:223-228, 1972.

• 11) Dobbins JW, Laurenson JP, Forrest Jr JN:Adenosine and adenosine analogues stimulate adenosine cyclic 3', 5'-monophosphate-dependent chloride secretion in the mammalian ileum. J Clin Invest 74:929-935, 1984.

• 12) De Jager S:Experiments and considerations on haemodynamics. J Physiol London 7:130-215, 1886.
  pubmed

• 13) Krogh A:The regulation of the supply of blood to the right heart. Scand Arch Physiol 27:227-248, 1912.

• 14) Coleman TG, Manning Jr RD, Norman Jr RA, et al:Control of cardiac output by regional blood flow distribution. Ann Biomed Eng 2:149-163, 1974.

• 15) Rothe CF:Reflex control of veins and vascular capacitance. Physiol Res 63:1281-1342, 1983.

• 16) Hirsch AT, Levenson DJ, Cutler SS, et al:Regional vascular responses to prolonged lower body negative pressure in normal subjects. Am J Physiol 257:H 219-H 225, 1989.

• 17) Price HL, Deutsch S, Marshall BE, et al:Hemodynamic and metabolic effect of hemorrhage in man, with particular reference to the splanchnic circulation. Circ Res 18:469-474, 1966.

• 18) Rowell LB, Freund PR, Brengelmann GL:Cutaneous vascular response to exercise and acute hypoxia. Respirat Environ Exercise Physiol 53:920-924, 1982.

• 19) Nadel ER, Fortney SM, Wenger CB:Effect of hydration state on circulatory and thermal regulations. J Appl Physiol 49:715-721, 1980.
  pubmed

• 20) Fortney SM, Nadel ER, Wenger CB, et al:Effect of acutealterations of blood volume on circulatory performance in humans. J Appl Physiol 50:292-298, 1981.
  pubmed

• 21) Sander-Jensen K, Mehlsen J, Stadeager C, et al:Increase in vagal activity during hypotensive lower-body negative pressure in humans. Am J Physiol 255:R 149-R 156, 1988.

• 22) Miwa M, Shinzato T, Nakai S, et al:Elucidation of the mechanism of dialysis-induced hypotension by mathematical circulatory block model. Abstracts of the 12th International Congress of Nephrology. pp. 330, 1993 (abstract).

• 23) Guyton AC:Textbook of Medical Physiology.
  pubmed

• 24) Johnson JM, Rowell LB, Niederberger M, et al:Human splanchnic and forearm vasoconstrictor responses to reductions of right atrial and aortic pressures. Circ Res 34:515-524, 1974.
  pubmed

• 25) Rubio R, Wiedmeier VT, Berne RM:Relationship between coronary flow and adenosine production and release. J Mol Cell Cardiol 6:561-566, 1974.
  pubmed

• 26) Kinet JP, Soyeur D, Balland N, et al:Hemodynamic study of hypotension during hemodialysis. Kidney Int 21:868-876, 1982.
  pubmed

• 27) Sakai K, Itagaki I, Mineshima M, et al:Water shift and solute transfer in osmotic hemopurification using high sodium fluid. Artif Organs 5 (Suppl):S 359-S 363, 1981.

• 28) Kimura G, Van Stone JC:Model prediction of plasma volumechanges induced by hemodialysis. J Lab Clin Med 104:932-938, 1984.

• 29) Maggiore Q, Pizzarelli F, Zoccali C, et al:Effect of extracorporeal blood cooling on dialytic arterial hypotension. Proc Eur Dial Transpl Assoc 28:597-602, 1981.

• 30) Coli U, Landini S, Lucatello S, et al:Cold as cardiovascular stabilizing factor in hemodialysis:Hemodynamic evaluation. Trans Am Soc Artif Intern Organs 24:71-75, 1983.

• 31) Brengelmann GL:Circulatory adjustments to exercise and heat stress. Annu Rev Physiol 45:191-212, 1983.
  pubmed

• 32) Gisolfi CV, Wenger CB:Temperature regulation during exercise:old concepts, new ideas. Exercise Sport Sci Rev 12:339-372, 1984.
  pubmed

• 33) Rowell LB:Human cardiovascular adjustments to exercise and thermal stress. Physiol Rev 54:75-159, 1974.
  pubmed

• 34) Rowell LB:Thermal stress, in Human circulation during physical stress, edited by Rowell LB, New York, Oxford University Press:pp 174-212, 1986.

• 35) Maggiore Q, Pizzarelli F, Sisca S, et al:Blood temperature and vascular stability during hemodialysis and hemofiltration. Trans Am Soc Artif Intern Organs 28:523-527, 1982.
  pubmed

• 36) Vagge R, Cavatorta F, Queirolo C, et al:Hemodynamic changes during acetate dialysis, bicarbonate dialysis and hemofiltration. Biochem Pharmacol 6:43-50, 1988.

• 37) Shaldon S, Beau MC, Deschodt G, et al:Vascular stability during haemofiltration. Trans Am Soc Artif Intern Organs 26:391-393, 1980.
  pubmed

• 38) Baldamus CA, Schoeppe W, Koch KM:Comparison of haemodialysis and postdilution haemofiltration on an unselected dialysis population. Proc Eur Dial Transpl Assoc 15:228-235, 1978.

• 39) Sherman RA, Torres F, Cody RP:Postprandial blood pressure changes during hemodialysis. Am J Kid Dis 12:37-39, 1988.
  pubmed

• 40) Zoccali C, Mallamaci F, Ciccarelli M, et al:Postprandial alterations in arterial pressure control during hemodialysis in uremic patients. Clin Nephrol 31:323-326, 1989.
  pubmed

• 41) Sawmiller DR, Chou CC:Adenosine plays a role in food-induced jejunal hyperemia. Am J Physiol 255:G 168-G 174, 1988.

• 42) Heseltine D, Dakkak M, Woodhouse K, et al:The effect of caffeine on postprandial hypotension in the elderly. J Am Geriat Soc 39:160-164, 1991.
  pubmed

• 43) Sherman RA, Torres F, Cody RP:The effect of red cell transfusion on hemodialysis-related hypotension. Am J Kid Dis 11:33-35, 1988.
  pubmed

• 44) Tekkanat KK, Port FK, Schmaltz S, et al:Excessive ATP degradation during hemodialysis against sodium acetate. J Lab Clin Med 112:686-693, 1988.
  pubmed

• 45) Vinay P, Cardoso M, Tejedor A, et al:Acetate metabolism during hemodialysis:Metabolic considerations. Am J Nephrol 7:337-354, 1987.
  pubmed

• 46) Daugirdas JT, Swanson V, Islam S, et al:Acetate causes endothelium-independent increases in cyclic AMP, but has no effect cyclic GMP, in the rat caudal artery. Am J Physiol 255:H 1378-H 1383, 1988.

• 47) Lenke D, Gries J, Kretzschmar R:Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzein-Forsch/Drug Res 31:1558-1565, 1981.

• 48) 下山博身, 佐野元規, 諏訪多順二, ほか:透析患者の低血圧に対する新しい薬剤Amezinium Metilsulfateの効果. 腎と透析25:501-506, 1988.

• 49) 中原保太郎, 布施順寛, 寺木良巳:透析時低血圧患者におけるamezinium Metilsulfateの使用成績. 薬理と治療21:1131-1138, 1993.

• 50) Ushioda E, Nuwayhid B, Kleinman G, et al:The contribution of the beta-adrenergic system to the cardiovascular response to hypovolemia. Am J Obstet Gynecol 147:423-429, 1983.

• 51) Shen YT, Knight DR, thomas Jr JS, et al:Relative rolesof cardiac receptors and arterial baroreceptors during hemorrhage in conscious dogs. Circ Res 66:397-405, 1990.

• 52) Hintze TH, Vatner SF:Cardiac dynamics during hemorrahge:Relative unimportance of adrenergic inotropic responses. Circ Res 50:705-713, 1982.

P.147 掲載の参考文献

• 1) Bardin T, Zingraff J, Shirahata T, et al:Hemodialysis-associated amyloidosis and beta-2microglobulin:Clinical and immunohistchemical study. Am J Med 83:419-424, 1987.

• 2) Warren DJ, Oteino LS:Carpal tunnel syndrome in patients on intermittent hemodialysis. Postgrad. Med J 51:450-452, 1975.

• 3) Ogawa H, Saito A, Hirabayashi N, et al:Amyloid deposition in systemic organs in long-term hemodialysis patients. Clin Nephrol 28:199-204, 1987.
  pubmed

• 4) Gejyo F, Yamasa T, Odani S, et al:A new form of amyloid protein assosiated with chronic hemodialysis was identified as β2microglobulin. Biochem. Biophys. Res. Commun. 129:701-706, 1985.

• 5) Gejyo F, Homma N, Suzuki Y, et al:Serum levels ofβ2microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Eng J Med 34:585-586, 1986.

• 6) Charra B, Calemard E, Lawrent G:Chronic renal failure treatment duration and mode:Their relevance to the late dialysis periarticular sindrome. Blood Purif 6:117-124, 1988.

• 7) 斎藤英彦, 田島達也, 牧野正晴, 他:血液透析患者にみられたアミロイド腱鞘滑膜炎を主病変とする手根管症候群20例の検討. 日手会誌, 2:928-932, 1986.

• 8) Kuntz D, Naveau B, Bardin T, et al:Destructive spondyloarthropathy in hemodialyzed patients:A new syndrome. Arthritis Rheum 27:369-375, 1984.
  pubmed

• 9) 丸山弘樹, 下条文武, 青柳竜治, 他:長期透析患者における破壊性脊椎関節症 (DSA) のMRI 所見. 腎と骨代謝 3:193-197, 1990.

P.158 掲載の参考文献

• 1) Coburn J W, Slatopolsky E:Vitamine D, Parathyroid hormone, and the Renal Osteodystrophies. In Brenner B M and Rector Jr, F C (eds.):The Kidney. Vol. 2, 4th ed, W.B. Saunders Co. Philadelphia, p 2036-2120, 1991.

• 2) Pierides AM, Edwards WG, Cullum UX, et al:Hemodialysis encephalopathy with osteomalacia fractures and muscle weakness. Kid Int 18:115-124, 1980.

• 3) Pei Y, Hercz G, Greenwood C, et al:Non-invasive prediction of aluminium bone disease in hemo-and peritneal dialysis patients. Kidney Int 41;1374-1382, 1992.

• 4) 吉田文直, 前田憲志, 鶴田良成, 他:血液透析患者の皮膚掻痒症に対するMS-Antigenの治療効果. 基礎と臨床 20(14);7081-7084, 1986.
  Medical*Online

• 5) 笠井健司, 川口良人. 臨床症状と診断. 黒川 清 他編:透析患者の骨病変-その見方と考え方-<改訂第3版>. 日本メディカルセンター(株)pp.105-130,1993.

• 6) 鶴田良成, 中根一憲, 成田真康, 他:長期血液透析患者の骨シンチグラムの定量化の検討. 腎と骨代謝. 2 (4), 481-488, 1989.

• 7) Slatopolsky E, Weets C, Thielan J, et al:Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihidroxycholecalciferol in uremic patients J Clin Invest 74;2136-2143, 1984.

• 8) 塚本雄介, 野村幸範, 丸茂文昭:ビタミンDパルス療法. 黒川 清 他編;透析患者の骨病変-その見方と考え方-<改訂第3版>. 日本メディカルセンター(株)pp. 271-276, 1993.

P.163 掲載の参考文献

• 1) Ritchie AC:Heterotopic calcification, 9th Ed, Led & Febiger, London, Vol. 1:156-158, 1990.

• 2) Kissane JM:Cell in jury and errors of metabolism, 9th Ed, The C. V. Mosby Company, Toronto, Vol 1:36, 1990.

• 3) Schrier RW:Gottschalk CW, Clinical disorders of phosphorus, calcium, and magnesium metabolism, 5th ed, Little, Brown and Company, Boston, Vol 3:2626, 1993.

• 4) Meema HE, Dimitrios G, Oreopoulos, et al:Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 32:388-394, 1987.

• 5) Alfrey AC, Solomens CC, Circillo J:Bone pyrophosphate in uremia and its association with extraosseous calcification. Clin Orthop 57:700-705, 1976.

• 6) Ono K:Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients. Clin Nephrol 26:239-243, 1986.
  pubmed

• 7) Massry SG:Divalent ion metabolism and renal osteodystrophy, 2nd Ed, Williams& Wilkins, Boltimore, vol. 2:1299-1302, 1989.

• 8) Contiguglia SR, Alfrey AC, Miller NL, et al:Nature of soft tissue calcification in uremia. Kidney Int 4:229-235, 1973.
  pubmed

• 9) Schrier RW, Gottschalk CW:Clinical disorders of phosphorus, calcium, and magnesium metabolism, 5th ed, Little, Brown and Company, Boston, Vol 3:3154-3155, 1993.

• 10) Polak BCP:Ophthalmological complications associated with hemodialysis, 2nd, Martinus nijhoff publishers, Boston, 742-744, 1983.

• 11) Berlyne GM, Manc MRCP, Shaw AB:Red eyes in renal failure, 7:4-7, 1967.

• 12) 横山武, 福西亮, 綿貫勤, ほか:動脈硬化症, 第2版, 金原出版, 東京, p 64-67, 1987.

• 13) 川口良人, 平沢由平:長期透析症例における異所性石灰化に関する研究. 平成2年度厚生科学研究. 腎不全医療研究事業研究報告書, pp. 143-148, 1991.

P.167 掲載の参考文献

• 1) Callen IR, Limarzi LR:Blood and bone marrow studies in renal disease. Am J Clin Pathol 20:3, 1950.
  pubmed

• 2) McGonigle RJS, Wallin JD, Shaddock RK, et al:Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25:437-444, 1984.

• 3) Eschback JW:Anemia of end-stage renal disease. Kidney Int 28:15, 1985.

• 4) Miyake T, Kung CKH, Goldwasser E:Purification of human erythropoietin. J Biol Chem 252;5558-5564, 1977.

• 5) Jacobs K, Shoemaker C, Rudersdorf R, et al:Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 318:806-810, 1985.

• 6) Lin F-K, Suggs S, Lin C-H, et al:Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci 82:7580-7584, 1985.
  pubmed

• 7) 平沢由平, 平嶋邦猛, 荒川正昭, 他:腎性貧血に対するrecombinant human erythropoietin(EPOCH)の長期投与による臨床検討. 腎と透析28:303, 1990.

• 8) 前田憲志, 飯田喜俊, 尾辻義人, ほか:わが国の慢性透析療法の現状 (1990年末現在). 日本透析療法学会雑誌, 25 (1):1-42, 1992.

• 9) Drueke T, Zins B, Naret C, et al:Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure. Adv. Nephrol 18:187-206, 1989.
  pubmed

• 10) Teruel JL, Pascual J, Liano F, et al:Hemodynamic changes in hemodialyzed patients during treatment with recombinant human erythropoietin. Nephron 58:135-137, 1991.
  pubmed

• 11) Nonnast-Daniel B, Deschodt G, Brunkhorst R, et al:Long-term effects of treatment with recombinant human erythropoietin on haemodynamics and tissue oxygenation in patients with renal anemia. Nephrol. Dial. Transplant 5 (6):444-448, 1990.
  pubmed

• 12) Sikole A, Polenakovic M, Spirovska V, Polenakovic B, et al:Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif. Organs 17:977-984, 1993.
  pubmed

• 13) Braunmann KM, Nonnast-Daniel B, Boning D, et al:Improved physical. performance after treatement of renal anemia with recombinant human erythropoietin. Nephron 58:129-134, 1991.

• 14) Evans RW, Rader B, Manninen L, et al:The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263 (6):825-830, 1990.

• 15) Marsh JM, Brown WS, Wolcott D, et al:rHuEPO treatement improves brain and cognitive function of anemic dialysis patients. Kidney International 39:155-163, 1991.

• 16) Schaefer RM, Paczek L, Heidland A:Improved immunoglobulin production by B lymphocytes from uremic patients treated with rHuEPO. Nephrol. Dial. Transplant. (abstract), 5:742-743, 1990.

• 17) Raine AEG:Seizures and hypertension events. Seminars in Nephrology 10 (2) Supple 1:40-50, 1990.

• 18) Takayama K, Nagai T, Kinugasa E, et al:Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients. Trans Am Soc Artif Intern Organs 37:M 187-M 188, 1991.

• 19) 飯田喜俊, 椿原美治, 篠田 暗, 他:保存期慢性腎不全患者に対するepoetin beta長期投与の成績. 腎と透析32:991, 1992.

• 20) 住友一夫, 土肥雪彦, 永井賢一, ほか:血清Ferritin値を指標とした慢性血液透析患者の鉄剤投与法の検討. 腎と透析14:693, 1983.

• 21) 平沢由平, 川口良人:rHuEPO使用ガイドライン作成に関する研究. 平成2年度厚生科学研究 『腎不全医療研究事業』研究報告書, 三村信英 (編), p. 87-89, 1991.

P.169 掲載の参考文献

• 1) 木原健, 東間紘:悪性腫瘍の治療. 臨床透析9:(7):245-246, 1993.

• 2) 太田善介, 天野哲基:免疫不全. 日本臨牀50:637-642, 1992.

• 3) 佐藤 威, 飛田美穂:腎癌を除く悪性腫瘍. 日本臨牀50:900-904, 1992.

• 4) 岸本武利, 和田誠次:腎不全患者の腫瘍免疫. 臨床透析9:(7):242-244, 1993.

P.173 掲載の参考文献

• 1) Goldblum SE, Reed WP:Host defenses and immunologic alterations associated with chronic hemodialysis. Annals of Internal Medicine 93:597-613 1980.
  pubmed

• 2) 日本透析学会統計委員会:わが国の慢性透析療法の現状 (1991年現在), 透析会誌26:17-30, 1993.

• 3) 前田貞亮:透析患者における検査値のとらえ方. White blood cell (WBC), 臨床透析8:21-4, 1992.

• 4) Harada T, Sakata H, Yasumori R, et al:Tuberculosis in patients undergoing hemodialysis. Kekkaku. 64 (10):641-8, 1989.
  pubmed

• 5) Lewis SL, Van-Epps DE, Chenoweth DE:Alterations in chemotactic factor-induced responses of neutrophils and monocytes from chronic dialysis patients. Clin Nephrol 30 (2):63-72, 1988.
  pubmed

• 6) Hirabayashi Y, Kobayashi T, Nishikawa A, et al:Oxidative metabolism and phagocytosis of polymorphonuclear leukocytes in patients with chronic renal failure. Nephron 49 (4):305-12, 1988.
  pubmed

• 7) Paul JL, Roch-Arveiller M, Man N K, et al:Influence of uremia on polymorphonuclear leukocytes oxidative metabolism in end-stage renal disease and dialized patients. Nephron 57 (4):428-32, 1991.

• 8) Craddock PR, Fehr J:Dalmasso AP, et al:Hemodialysis leukopenia:Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 59:879-88, 1977.
  pubmed

• 9) Blomquist S, Malmros L, Martensson L, et al:Absence of lung reactions after complement depletion during dialysis:an experimental study in pigs. Artif Organs 15 (5):397-401, 1991.

• 10) Martin-Malo A, Castillo D, Castro M, et al:Biocompatibility of dialysis membranes:a comparative study. Nephrol Dial Transplant. 6 Supple 2;55-8, 1991.

• 11) Schaefer RM, Heiland A, Horl WH:Release of leukocyte elastase during hemodialysis. Effect of different dialysis membranes. Contr Nephrol 46:109-11, 1985.

• 12) Schaefer RM, Herfs N, Ormanms W, et al:Change of elastase and cathepsin G content in polymorphonuclear leukocytes during hemodialysis. Clin Nephrol 29 (6):307-11, 1988.

• 13) Sengar DPS, Rashid A, Harris JA:In vitro celluler immunity and in vivo delayed hypersensitivity in uremic patients maintained on hemodialysis. Int Arch Allergy 47:829-38, 1974.

• 14) Selroos O, Pasternack A, Virolains M:Skin test sensitivity and antigen induced lymphocyte transformation in uremia. Clin Exp Immunol 14:365-70, 1973.

• 15) Kurz P, Koler H, Muerer S, et al:Impaired Cellular immune responses in chronic renal failure:Evidence for a T cell defect. Kidney Int 29:1209-14, 1986.

• 16) Newberry WM, Sanford JP:Defective cellular immunity in renal failure:Depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. J Clin Invest. 50:1262-71, 1971.

• 17) Nakhla LS, Goggin MJ:Lymphocyte transformation in chronic renal failure. Immunology 24:229-35, 1973.
  pubmed

• 18) Nelson J, Ormrod DJ, Miller TE:Host immune status in uremia. VI. Leucocytic response to bacterial infection in chronic renal failure. Nephron 39:21-5, 1985.
  pubmed

• 19) Crosnier J:Hepatitis B in hemodialysis:Vaccination against HBs antigen. Proc EDTA. 18:231-240, 1981.

• 20) Paczek L, Schaefer RM, Heidland A:Dialysis membranes decrease immunoglobulin and interleukin-6 production by peripheral blood mononuclear cells in vitro. Nephrol Dial Transplant 6 (Supple 3):41-4, 1991.

• 21) Gaciong Z, Alexiewicz JM, Linker-Israeli M, et al:Inhibition of immunoglobulin production by parathyroid hormone. Implications in chronic renal failure. Kidney Int 40 (1):96-106, 1991.
  pubmed

• 22) Schaefer RM, Paczek I, Berthold G, et al:Improved immunoglobulin production in dialysis patients treated with recombinant erythropoietin. Int J Artif Organ 15 (4):204-8, 1993.

• 23) 中林公正, 鈴木道彦, 長沢俊彦:透析患者における検査値のとらえ方. Immunoglobulin, 臨床透析8:199-202, 1992.

• 24) Versluis DJ, Beyer WEP, Masurel N, et al:Influenza vaccination in dialysis and transplant patients. Antiviral Research. Suppl 1:289-92, 1985.

• 25) 中林公正, 田中宇一郎, 長沢俊彦:透析患者における検査値のとらえ方. Autoantibody, 臨床透析8:203-7, 1992.

• 26) Taylor CJ, Ting A, Morris PJ:Production and characterization of human monoclonal lymphocytotoxic autoantibodies from a renal dialysis patients. Tissue Antigens 37 (3):112-20, 1991.
  pubmed

• 27) Henderson LW, Koch KM, Dinarello CA, et al:Hemodialysis hypotension:The interleukin hypothesis. Blood Purifi 1:3-8, 1983.

• 28) Shaldon S, Koch KM, Dinarello CA:Interleukin-1 activation and acute phase response during hemodialysis. Contr Nephrol 61:18-26, 1988.

• 29) Herbelin A, Nguyen AT, Zingraff J, et al:Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factorα. Kidney Int 37:116-25, 1990.

• 30) Schaefer RM, Paczek I, Heiland A:Cytokine production by monocytes during haemodialysis. Nephrol Dial Transplant 6 (Supple 2):14-7 1991.

• 31) Pereira BJ, Poutsiaka DD, King AJ, et al:In vitro production of interleukin-1 receptor antagonist in chronic renal failure CAPD and HD. Kidney Int 42 (6):1419-24, 1992.
  pubmed

• 32) Haubitz M, Kloppel B, Lonnemann G, et al:In vitro production of interleukin-1 from blood mononuclear cells of patients on chronic hemodialysis therapy. Clin Nephrol 38 (1):30-5, 1992.
  pubmed

• 33) Friedlander MA, Hilbert CM, Wu YC, et al:Role of dialysis modality in response of blood monocytes and peritoneal macrophages to endotoxin stimulation. Am J Kidney Dis 22 (1):11-23, 1993.
  pubmed

P.184 掲載の参考文献

• 1) わが国の慢性透析療法の現況-1991年12月31日現在. 日本透析療法学会.

• 2) Goldstein DA, Massry SG:Diabetic nephropathy;Clinical course and effect of hemodialysis. Nephron 20:286, 1978.
  pubmed

• 3) Weidmann P, Beretta-Piccoli C, Trost BN:Pressor factors and responsiveness in hyper-tension accompanying diabetes mellitus. hypertension 7 (suppl II):II-33, 1985.

• 4) Friedman EA:Diabetic nephropathy:Strategies in prevention and management. Kidney Int 21:780, 1982.
  pubmed

• 5) 渡辺有三, 山崎親雄:糖尿病透析患者の視力障害の背景並びに対策, 透析会誌22:1379, 1989.

• 6) 厚生省糖尿病調査班:糖尿病性腎不全症に対する長期透析適応基準, 1989.

• 7) 馬場園哲也, 佐中孜, 平田幸正:糖尿病性腎不全患者の透析導入後の予後からみた早期計画導入の重要性. 透析会誌22:1324, 1989.

• 8) 岡本克章, 白井大禄, 藤田芳正, 他:糖尿病性腎症による血液透析患者に合併した急性心筋梗塞の検討. 透析会誌25:1105, 1992.

• 9) 清水賢巳, 竹田亮祐:*進展増悪因子-心不全, 冠不全. 新・糖尿病性腎症-発症予防と進展阻止のために, 繁田幸雄, 海津嘉蔵編, 医学書院, p 256, 東京, 1992.

• 10) Vigorito C, Betocchi S, Bonzani G, et al:Severity of coronary artery disease in patients with diabetes mellitus. Angiographic study of 34 diabetic and 120 nondiabetic patients. Am Heart J 100:782, 1980.
  pubmed

• 11) Bennett WM, Kloster F, Rosch J, et al:Natural history of asymptomatic coronary arteriographic lesions in diabetic patients with end-stage renal disease. Am J Med 65:779, 1978.
  pubmed

• 12) Hamby RI, Zoneraich S, Sherman L:Diabetic cardiomyopathy. JAMA 229:1749, 1974.
  pubmed

• 13) Factor SM, Okun EM, Minase T:Capillary microaneurysms in the human diabetic heart. N Engl J Med 302:384, 1980.

• 14) Watschinger B, Brunner C, Wagner A, et al:Left Ventricular Diastolic Impairment in Type 1 Diabetic Patients with Microalbuminuria. Nephron 63:145, 1993.
  pubmed

• 15) 前田憲志:Sodium gradient method (SGM). 透析会誌, 12:213, 1979.

• 16) Maeda K, Kawaguchi S, Kobayashi S, et al:Cell-Wash Dialysis (CWD). Trans Am Soc Artif Organs 26:213, 1980.
  pubmed

• 17) Makita Z, Radoff S, Rayfield EJ, et al:Cerami A, Vlassara H:Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836, 1991.
  pubmed

P.192 掲載の参考文献

• 1) Straumann E, Meyer B, Misteri M, et al:Aortic and mitral valve disease in patients with end stage renal failureon longterm haemodialysis. British Heart Journal. vol. 67 no. 3:236-239, 1992.

• 2) Meissner MD, Panidis IP, McAllister M, et al:Echocardiographic and doppler findings in patient with chronic renal failure on hemodialysis. American journal of noninvasive cardiology. vol. 4 no. 1:8-14, 1990.

• 3) 鷲尾昌一, 小野山薫, 奥田誠也, 他:糖尿病透析患者の左室肥大に関する検討:日本透析療法学会雑誌, 24 (7):929-932, 1991.

• 4) 鷲尾昌一, 槇田裕之, 藤井弘二, 他:慢性透析患者の貧血と左室肥大:臨床と研究68 (10):3053-3056, 1991.

• 5) 井上優, 井岡二郎, 沢田克徳,他:透析患者の心血行動態の特徴-心エコーを用いての検討:臨床透析7 (6):707-711, 1991.

• 6) 米沢嘉啓, 土居義典, 浜重直久, 他:長期血液透析患者における心肥大心機能に関する研究-心エコー法による2年間の経過観察:循環器科21 (5):467-474, 1987.

• 7) 梶原長雄, 内山隆久, 山下真, 他:慢性維持透析患者の心機能-心エコー図による左室拡張能の検討:日本腎臓学会誌29 (10):1287-1293, 1987.

• 8) 辻林隆, 杉本圭市, 丹羽明博, 他:等尺性負荷による肥大心の心機能評価. 最新医学41 (2):387-389, 1986.

• 9) Ishizuka T, Hashimoto H, Hayashi T, et al:Cardiac abnormalities on echocadiograms and phonocardiograms in patients with end stage chronic renal failure.; Dokkyo Journal of Medical Sciences 11 (2):157-168, 1984.

• 10) Goldstein DH, Nagar C, Flowers NC, et al:Clinically Silent pericardial effusions in patient on longterm hemodialysis. Pericardial effusions in hemodialysis.;Chest 77 (6):744-747, Dec. 1977.

• 11) Kahn JK, Rutherford BD, Hartzler GO, et al:Shortand longterm outcome of perucutaneus transluminal coronary angioplasty in chronic dialysis patients.;American Heart Journal 119 (3) pt. 1:484-489, Mar 1990.

• 12) 村松俊哉, 矢部喜正, 池田基昭, 他:6th PTCAにより閉塞をまぬがれた慢性透析患者の一例:日独医報37 (2):304-305, 1992.

• 13) 小柳俊哉:透析患者に於けるCABG:Coronary 8 (3):271-276, 1991.

• 14) 石黒源之, 幾高敏晴, 平野高弘, 他:慢性腎不全患者における非イオン性造影剤イオパミドール (イオパミロン) の検討-血中ヨウ素濃度からの検討-:日独医報34 (2):202-209, 1989.

P.195 掲載の参考文献

• 1) 日台英雄, 内田龍生, 千葉哲男, 他:慢性腎不全患者に合併する嚢胞性疾患. 腎と透析28; 417, 1990.

• 2) Dunnill MS, Millard PR, Oliver D:Acquired cystic disease of the kidneys:a hazard of long-term intermittent maintenance haemodialysis. J Clin Path 30;868, 1977.
  pubmed

• 3) Ishikawa I:Uremic acquired cystic disease of kidney. Urology 26;101, 1985.
  pubmed

• 4) 石川 勲:透析患者の画像診断-CTを中心に. 腎と透析27;1069, 1989.

P.199 掲載の参考文献

• 1) Fluckiger R, Harmon W, Meier W, et al:Hemoglobin carbamylation in uremia. New Engl J Med 304:823-827, 1981.
  pubmed

• 2) Giovannetti S, Balestri PL, Barsotti G:Methylguanidine in uremia. Arch Intern Med 131:709-713, 1973.
  pubmed

• 3) Horowitz HI, Stein IM, Cohen BD, et al:Further studies on the platelet-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 49:336-345, 1970.
  pubmed

• 4) Simmenhoff ML, Glinn HE:Toxicity of aliphatic amines in uremia. Trans Am Soc Artif Intern Organs 23:560-564, 1977.

• 5) Radtke HW, Rege AB, LaMarche MB, et al:Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure, J Clin Invest 67:1623-1629, 1981.
  pubmed

• 6) Kramer HK, Gospodinov D, Kramer HJ, et al:Inhibition of transport-ATPase by uremic toxins. Proc Eur Dial Transplant Assoc 9:521-528, 1972.

• 7) Clements RS, De Jesus PV, Winegrad AT:Raised plasma myoinositol levels in uraemia and experimental neuropathy. Lancet 1:1137-1141, 1973.
  pubmed

• 8) Bogin E, Massry SG, Levi J, et al:Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest 69:1017-1025, 1982.
  pubmed

• 9) Bogib E, Massry SG, Harary I, et al:Effect of parathyroid hormone on rat heart cells. J Clin Invest 67:1215-1227, 1981.

• 10) Miyata T, Oda O, lnagi R, et al:β2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243-1252, 1993.

P.208 掲載の参考文献

• 1) Millard LC:Compt Rend Acad Sci 154:66, 1912.

• 2) Rahbar S:Hemoglobin H disease in two Iranian families. Clin Chim Acta 20:381, 1968.
  pubmed

• 3) Monnier VM, Cerami A:Nonenzymatic browning in vivo:possible process for aging of long-lived proteins. Science 211:491, 1981.
  pubmed

• 4) Miller K, Michael AF:Immunopathology of renal extracellular membranes in diabetes mellitus:Specificity of tubular basement-membrane immunofluorescence. Diabetes 25:701, 1976.
  pubmed

• 5) Brownlee M, Pongor S, Cerami A:Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen. Role in the in situ formation of immune complexes. J Exp Med 158:1739, 1983.
  pubmed

• 6) Stevens VJ, Vlassara H, Avati A, et al:Nonenzymatic glycosylation of hemoglobin. J Biol Chem 252:2998, 1977.

• 7) Slight SH, Feather MS, Ortwerth BJ:Glycation of lens proteins by the oxidation products of ascorbic acid. Biochem Biophys Acta 1038:367, 1990.
  pubmed

• 8) Brownlee M, Cerami A, Vlassara H:Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315, 1988.
  pubmed

• 9) Baynes JW, Monnnier VM:The Maillard reaction in aging, diabetes and nutrition. Prog Clin Biol Res 304:1, 1989.

• 10) Brownlee M, Vlassara H, Cerami A:Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Int Med 101:527, 1984.
  pubmed

• 11) Ponger S, Ulrich PC, Bencsath FA, et al:Aging of proteins:isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci USA 81:2684, 1984.

• 12) Njoroge FG, Sayre LM, Monnier VM:Detection of glucosederived pyrrole compounds during Maillard reaction under physiological conditions. Carbohydr Res 167:211, 1987.

• 13) Sell DR, Monnier VM:Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 264:21597, 1989.
  pubmed

• 14) Nakamura K, Hasegawa T, Fukunaga Y, et al:Crossline A and B as candidates for the A fluorophores in ase and diabetes-related cross-lonked proteins, and their diacetates producted by Maillard reaction of α-N-acetyl-L-lysine with D-glucose. J Chem Soc Chem Commun 14:992, 1992.

• 15) Witztum JL, Koschinsky T:Metabolic and immunological consequences of glycation of low density lipoproteins. Progr Clin Biol Res 304:219, 1989.

• 16) Brownlee M:Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 32:680, 1983.
  pubmed

• 17) Brownlee M, Vlassara H, Cerami A:Inhibition of heparincatalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes. Diabetes 33:532, 1984.
  pubmed

• 18) Brownlee M, Cerami A, Vlassara H:Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315, 1988.
  pubmed

• 19) Vlassara H, Brownlee M, Cerami A:Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. J Exp Med 160:197, 1984.
  pubmed

• 20) Vlassara H, Brownlee M, Cerami A:High-Affinity-receptor-mediated uptake and degradation of glucose-modified proteins:a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82:5588, 1985.
  pubmed

• 21) Kirstein M, Brett J, Radoff S, et al:Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor:role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 87:9010, 1990.
  pubmed

• 22) Vlassara H, Brownlee M, Manogue KR, et al:Cachectin/TNF and IL-1 induced by glucose-modified proteins:role in normal tissue remodeling. Science 240:1546, 1988.
  pubmed

• 23) Skolnik EY, Yang Z, Makita Z, et al:Human and rat mesangial cell receptors for glucosemodified proteins:potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 174:931, 1991.
  pubmed

• 24) Makita Z, Radoff S, Rayfield EJ, et al:Advanced glycosylation end products in patients with diabetic nephropathy N Engl J Med 325:836, 1991.
  pubmed

• 25) Makita Z, Vlassara H, Cerami A, et al:Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133, 1992.
  pubmed

• 26) Drueke TB:Beta-2-microglobylin amyloidosis and renal bone disease. Miner. Elecrtolyte Metab 17:261, 1991.
  pubmed

• 27) Gejyo F, Yamada T, Odani S, et al:A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 129:701, 1985.

• 28) Gorevic PD, Munoz PC, Casey TT, et al:Polymerization of intactβ2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis. Proc Natl Acad Sci USA 83:7908, 1986.

• 29) Shirahama T, Skinner M, Cohen AS, et al:Histochemical and immunohistochemical characterization of amyloid associated with chronic hemodialysis as beta 2-microglobulin. Lab Invest 53:705, 1985.
  pubmed

• 30) Gejyo F, Odani S, Yamada T, et al:Beta 2-microglobulin:a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 30:385, 1986.
  pubmed

• 31) Linke RP, Bommer J, Ritz E, et al:Amyloid kidney stones of uremic patients consist of beta 2-microglobulin fragments. Biochem Biophys Res Commun 136:665, 1986.
  pubmed

• 32) Linke RP, Hampl H, Lobeck E, et al:Lysine-specific cleavage of beta 2-microglobulin in amyloid deposits associated with hemodialysis. Kidney Int 36:675, 1989.

• 33) Odani H, Oyama R, Titani K, et al:Purification and complete amino acid sequence of novel β2-microglobulin. Biochem Biophys Res Commun 168:1223, 1990.

• 34) Miyata T, Oda O, Inagi R, et al:β2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243, 1993.

• 35) Horiuchi S, Araki N, Morino Y:Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. J Biol Chem 266:7329, 1991.
  pubmed

• 36) Miyata T, Inagi R, Wada Y, et al:Glycation of human β2-microglobulin in patients with hemodialysis-associated amyloidosis:identification of the glycated sites. Biochemistry 33:12215, 1994.

• 37) Miyata T, Inagi R, Iida Y, et al:Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis:induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-a and interleukin 1. J Clin Invest 93:521, 1994.

• 38) Depierreux M, Goldman M, Fayt I, et al:Osteoarticular amyloidosis associated with haemodialysis:an immunoultrastructural study. J Clin Pathol 41:158, 1988.
  pubmed

• 39) Theaker JM, Raine AEG, Rainey AJ, et al:Systemic amyloidosis of β2-microgrobulin type:a complication of longterm haemodialysis. J Clin Pathol 40:1247, 1987.

• 40) Saklatvala J:Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322:547, 1986.
  pubmed

• 41) Bertolini DR, Nedwin GE, Bringman TS, et al:Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516, 1986.
  pubmed

• 42) Gowen M, Wood DD, Ihrie EJ, et al:An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306:378, 1983.
  pubmed

• 43) Pacific R, Rifas L, Teitelbaum S, et al:Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporsis. Proc Natl Acad Sci USA 84:4616, 1987.

• 44) Dayer J-M, Beutler B, Cerami A:Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162:2163, 1985.
  pubmed

• 45) Harris ED, Jr:In Textbook of Rheumatology. W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, editors. W. B. Saunders Co., Philadelphia, 886, 1985.

• 46) Akira S, Hirano T, Taga T, et al:Biology of multifunctional cytokines:IL-6 and related molecules (IL-1 and TNF). FASEB J 4:2860, 1990.
  pubmed

• 47) Horowiz MC:Cytokines and estrogen in bone:anti-osteoporotic effects. Science 260:626, 1993.

• 48) Girasole G, Jilka RL, Passeri G, et al:17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro:a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89:883, 1992.
  pubmed

P.216 掲載の参考文献

• 1) Brown MS, Goldstein JL:Lipoprotein metabolism in the macrophage:Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52:223-261, 1983.
  pubmed

• 2) Chan MK, Varghese Z, Moorhead JF:Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 19:625-637, 1981.

• 3) Verschoor L:Triglyceride turnover in severe chronic non-nephrotic renal failure. Metabolism 8:879-883, 1979.

• 4) Bagdade JD, Yee E, Wilson DE, et al:Hyperlipidemia in renal failure;studies of plasma lipoproteins, hepatic triglyceride production and tissure lipoprotein lipase in a chronically uremic rat model. J Lab Clin Med 91:176-186, 1978.

• 5) Mordasini R, Frey F, Flury W, et al:Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med 297:1362-1366, 1977.
  pubmed

• 6) 湯川 進, 森下茂, 宮井利彦, ほか:透析患者の血清VLDL-IDL異常とPHLA (LPLおよびH-TGL活性) 変動. 日腎誌25:717-722, 1983.

• 7) Goldberg A, Sherrard D, Brunzell J:Hypertriglyceridemia in hemodialysis patients:dual defect of adipose tissue lipoprotein lipase. Clin Res 24:361, 1976.

• 8) Murase T, Cattran DC, Rubenstein B, et al:Inhibition of lipoprotein lipase by uremic plasma. A possible cause of hypertriglyceridemia. Metabolism 24:1279-1286, 1975.
  pubmed

• 9) Di Giulio S, Lacour B, Man NK, et al:Postheparin lipolytic activity in uremic patients treated by hemofiltration. Contrib Nephrol 29:143-148, 1982.
  pubmed

• 10) Rapoport J, Aviram M, Chaimovitz C, et al:Defective high-density lipoprotein composition in patients on chronic hemodialysis:A possible mechanism for atherosclerosis. N Engl J Med 299:1326-1330, 1978.
  pubmed

• 11) Averna MR, Barbagallo CM, Galione A, et al:Serum apolipoprotein profile of hypertriglyceridemic patients with chronic renal failure on hemodialysis:A comparison with type IV hyperlipoproteinemic patients. Metabolism 38:601-602, 1989.
  pubmed

• 12) Matsui N, Nakamura Y, Shinoda T, et al:The effect of heparin-free dialysis on abnormal lipid metabolism in patients on regular dialysis treatment. Proc Eur Dial Transplant Assoc 17:253-258, 1980.
  pubmed

• 13) Huttunen JK, Pasternack A, Vanttinen T, et al:Lipoprotein metabolism in patients with chronic uremia. Effect of hemodialysis on serum lipoprotein and postheparin plasma:triglyceride lipaemia. Acta Med Scand 204:211-218, 1978.

• 14) Leschke M, Rumpf KW, Eisenhauer T, et al:Quantitative assessment of carnitine loss during hemodialysis and hemofiltration. Kideny Int 24 (Suppl):S 143-S 146, 1983.

• 15) Lacour B, Di Giulio S, Chanard J, et al:Carnitine improves lipid anomalies in haemodialysis patients. Lancet ii:763-765, 1980.

• 16) Maeda K, Shinzato T, Kobayakawa H:Effects of L-carnitine administration on shortchain fatty acid (acetic acid) and long-chain fatty acid metaboism during hemodiaysis. Nephron 51:355-361, 1989.

• 17) Minamisono T, Wada M, Akamatsu A, et al:Dyslipoproteinemia (a remnant lipoprotein disease) in uremic patients on hemodialysis. Clin Chim Acta 84:163-172, 1978.
  pubmed

• 18) Nestel PJ, Fidge NH, Tan MH:Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 307:329-333, 1982.
  pubmed

• 19) Mahley RW:Atherogenic hyperlipoproteinemia. Med Clin North Am 66:375-402, 1982.
  pubmed

• 20) 湯川 進, 宗 正敏, 後藤哲也, ほか:腎不全時のMDAリッチ:LDLと腎病態. 腎不全1:49-55, 1989.

• 21) 日比野彰, 湯川 進, 前田孝夫, ほか:ヒト単球由来マクロファージにおける生体由来過酸化LDLの代謝. 動脈硬化15:1097-1100, 1987.

• 22) Bagdade JD, Albers JJ:Plasma high-density lipoprotein concentrations in chronic hemodialysis and renal-transplant patients. N Engl J Med 296:1436-1439, 1977.
  pubmed

• 23) Chan MK, Ramdial L, Varghese Z, et al:Plasma lecithin-cholesterol acyltransferase acitivities in uraemic patients. Clin Chim Acta 119:65-72, 1982.

• 24) Sandkamp M, Funke H, Schulte H, et al:Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 36:20-23, 1990.

• 25) Parra HJ, Mezdour H, Cachera C, et al:Lp (a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 33:721, 1987.
  pubmed

• 26) 竹越忠美, 木藤知佳志, 山崎義亀興:維持血液透析患者におけるLp (a) リポ蛋白の臨床的意義について. 日腎誌 32:667-671, 1990.

• 27) 大橋宏重, 小田 寛, 松野由紀彦, ほか:慢性血液透析患者のLp (a) リポタンパク-とくにアポ(a)アイソフォームよりの検討-. 日腎誌35:823-828, 1993.

• 28) Wass VJ, Jarrett RJ, Meilton V, et al:Effect of a long-term fat-modified diet on serum lipoprotein levels of cholesterol and triglyceride in patients on home haemo dialysis. Clin Sci 60:81-86, 1981.

• 29) Tsukamoto Y, Okubo M, Yoneda T, et al:Effect of a polyunsaturated fatty acid-rich diet on serum lipids in patients with chronic renal failure. Nephron 31:236-241, 1982.
  pubmed

• 30) Goldberg AP, Hagberg JM, Delmez JA, et al:Exercise training corrects abnormal lipid and carbohydrate metabolism in hemodialysis patients. Trans Am Soc Artif Int Organs 25:431-437, 1979.

• 31) Cattran DC, Fenton SSA, Wilson DR, et al:Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis. Ann Intern Med 85:29-33, 1976.

• 32) Tsujita Y, Kuroda M, Shimada Y, et al:CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase:tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 877:50-60, 1986.
  pubmed

• 33) 三木茂裕, 海部泰夫, 小野茂男, ほか:維持透析患者の高脂血症に対するプラバスタチンの臨床的有効性について. 腎と透析30:113-119, 1991.

• 34) Vacha GM, Giorcelli G, Siliprandi N, et al:Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients. Decisive role of low levels of high-density lipoprotein-cholesterol. Am J Clin Nutr 38:532-540, 1983.
  pubmed

• 35) 湯川 進. 透析患者の脂質代謝異常. 透析会誌25.87-92, 1992.

• 36) 湯川 進, 刀禰佳典, 園部美弥彦, 湯川彰英, 日比野彰:透析患者における脂質代謝異常とその治療. JJPEN 12:273-277, 1990.

• 37) Rylance PB, Gordge MP, Saynor R, et al:Fish oil modifies lipid and reduces platelet aggregability in hemodialysis patients. Nephron 43:196-202, 1986.
  pubmed

• 38) Rolf N, Tenshert W, Lison AE:Results of a long-term administration of omega-3 fatty acid in haemodialysis patients with dyslipoproteinaemia. Nephrol Dial Transplant 5:797-801, 1990.

P.223 掲載の参考文献

• 1) Bourgoignie JJ, Jacob AI, Sallman AL, et al:Water, electrolyte, and acid-base abnormalities in chronic. renal failure. Semin. Nephrol 1;91, 1981.

• 2) 南学正臣, 黒川 清:腎不全の進行に伴う水電解質異常. 臨床透析7:1073, 1991.

• 3) DeBold AJ, Borenstein HB, Veress AT, et al:Arapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28;89, 1981.

• 4) Port FK, Johnson WJ, Klass DW:Prevention of dialysis disequilibrium syndrome by use of high. sodium concentration in the dialysate. Kidney Int 3:327, 1973.
  pubmed

• 5) Maeda K, Kawaguchi S, Kobayashi S, et al:Cell-wash dialysis. Transactions ASAIO, 26:213, 1980.

• 6) Bastl C, Hayslett Jp, Binder HJ:Increased large intestinal secretion of potassium in renal. insufficiency. Kedney Int 12:9, 1977.

• 7) 猿田享男:I.水・電解質代謝異常 4.高カリウム血症と低カリウム血症, 日内誌80:174, 1991.

• 8) Kurokawa K:Calcium-regulating hormones and the kidney. Kidney Int 32:760, 1987.
  pubmed

• 9) 吉富宏治, 今井 正:腎臓のカルシウム輸送系. 腎と骨代謝3:283, 1990.

• 10) McSheehy PMJ, Chambers TJ:Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endcrinol 118:824, 1986.

• 11) Slatopolsky E, Bricker NS, et al:The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4;141, 1973.
  pubmed

• 12) Massry SG, Coburn JW, Lee DBN, et al:Skeltal resistance to parathyroid hormone in renal failure:Ann Intern Med 78:357, 1973.

• 13) Korkor AB:Redused binding of [3H] 1,25 (OH)2D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316:1573, 1987.

• 14) 南学正臣, 深川雅史:腎性骨異栄養症. 腎不全. 黒川 清編, p 154, 南江堂, 東京, 1991.

• 15) Pierides AM, Edwards WG, Cullum UX, et al:Hemodialysis encephalopathy with osteomalacia fractures and muscle weakness:Kid Int 18:115, 1980.

• 16) 岡田勝, 酒井清孝, 渡辺哲夫, 他:透析膜における無機リンイオンの膜透過性. 人工臓器 19:805, 1990.

• 17) 大平整爾, 安部憲司, 長山 誠, 他:血液透析によるリン除去率量の検討. 透析会誌21; 1021, 1988.

• 18) 臼井昭子:低リン食の実際. 臨床透析7:1499, 1991.

• 19) Slatopolsky E, Weert C, Thielan J, et al:Maked suppression of secondary hyperparathyroidism by intravenous administration of 1, 25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136, 1984.

• 20) Fukagawa M, Okazaki R, Takano K, et al:Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Eng J Med 323:421, 1990.

• 21) Tsukamoto Y, Nomura Y, Takahashi Y, et al:The "oral 1,25-dihydroxyvitamin D3 pulse therapy" in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 57:23, 1991.

P.226 掲載の参考文献

• 1) 越川昭三:腎による酸塩基平衡の調節. 臨床生理学シリーズ4, [腎臓]. 黒川 清, 今井 正編, 南江堂, 東京, 1989.

• 2) Cogan M, Gand Rector FC Jr.:Acid-base disorders. Brenner BM, Rector FC Jr. (ed.):The kidney. 737-804, W. B. Saunders, Philadelphia, 1991.

• 3) 安藤明利, 岡本玖美, 杉野信博:酸塩基平衡とanion gap. 腎と透析15:17, 1983.

• 4) 杉野信博, 荒井純子, 安藤明利:腎不全と酸塩基平衡異常. 酸塩基平衡. 越川昭三編, 中外医学社, 東京, p 383-386, 1987.

• 5) 上原 元:酸塩基平衡の異常. 臨床透析7:1143-1149, 1991.

• 6) Mion CM:Substitution of acetate for sodium bicarbonate in the bath fluid for hemodialysis. Transactions ASAIO 10:110-113, 1964.

• 7) Shaldon S, Bean C, Deschodt G, et al:Vascular stability during hemofiltration. Transactions ASAIO 26:391-393, 1980.

• 8) Iseki K, Onoyama K, Maeda T, et al:Comparison of hemodynamics induced by conventional acetate hemodialysis, bicarbonate hemodialysis and ultrafiltration. Clinical Nephrology 14:294-298.1980.
  pubmed

P.239 掲載の参考文献

• 1) Maroni BJ, Steinman TI, Mitch WE:A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27:58-65, 1985.
  pubmed

• 2) Borah MF, Schoenfeld PY, Gotch FA, et al:Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 14:491-500, 1978.
  pubmed

• 3) Jeevanandam M, Legaspi A, Lowry SF, et al:Effect of total parenteral nutrition on whole body protein kinetics in cachectic patients with benign or malignant disease. JPEN 12:229-236, 1988.
  pubmed

• 4) Gotch FA, Sargent JA:A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 28:526-534, 1985.
  pubmed

• 5) Daugirdas JT:The post:pre-dialysis plasma urea nitrogen ratio to estimate K t/V and NPCR:mathematical modeling. Int J Artif Organs 12:411-419, 1989.

• 6) Jindal KK, Golsdtein MB:Kinetic modelling in chronic hemodialysis:Benefits, problems, and practical solutions. Seminars in Dialysis 1:82-85, 1988.

• 7) Gotch FA, Sargent JA, Keen ML, et al:Individualized, quantified dialysis therapy of uremia. Proc Clin Dial Transpl Forum 4:27-35, 1974.

• 8) Shinzato T, Nakai S, Fujita Y, et al:Determination of Kt/V and protein catabolic rate using pre-and postdialysis blood urea nitrogen concentration. Nephron 67:280-290, 1994.

• 9) Farrel PC, Hone PW:Dialysis induced catabolism. Am J Clin Nutr 33:1417-1422, 1980.

P.246 掲載の参考文献

• 1) Bennett WM:Drugs and renal disease. Churchill Livingstone Inc. 1986.

• 2) Martines-Maldonaado M:Handbook of Remal Therapeutics. Plenum Medical Book Co., New York, 1983.

• 3) 高田寛治:腎機能不全症例投与量の決定法. 日本臨牀39 (春季増刊号);821-825, 1981.

• 4) 山作房之輔:特殊病態における化学療法, 腎不全・透析患者 日内誌79:1646-1652, 1990.

• 5) 透析患者への薬剤, 1991, 臨床透析7 (7):1991.

• 6) 前田憲志, 飯田善俊ら:わが国の慢性透析療法の現状 (1990年末現在). 日本透析療法学会雑誌 25:1-42, 1992.

• 7) 平澤由平, 甲田豊:透析室薬剤の選び方と使い方, 南江堂, 1993.

• 8) Shils ME:Renal Disease and the metabolic effects of tetracycline. Ann Intern Med 58:389, 1963
  pubmed

• 9) 多川斉:透析患者の循環器ハンドブック. 日本メディカルセンター, 1987.

• 10) 越川昭三, 太田和夫:Current review透析療法2, 中学医学社, 1992.

• 11) 伊東春樹, 谷口興一:血液透析患者の突然死と不整脈. 日腎誌29:791, 1987.

• 12) 前波輝彦, 萩本剛一, 石田尚志:不整脈. 腎と透析27 (臨時増刊号):369-371, 1989.

• 13) Lown B, Wolf M:Approaches to sudden death from coronary heart disease. Circulation 44:130, 1971.
  pubmed

• 14) The cardiac arrhythmia suppression trial (CAST) investigators:Preliminary report:Effect of encainide and flecained on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New E J Med 321:406-411, 1989.

P.248 掲載の参考文献

• 1) 杉本孝一, 後藤英司, 塩之入洋:利尿薬, 降圧薬. 腎障害患者への投薬. 98-103, ミクス, 1988.

• 2) 平澤由平, 甲田 豊:利尿薬 (ループ性利尿薬). 透析室薬剤の選び方と使い方, 85, 南江堂, 1993.

• 3) 長瀬光昌:特殊病態下の薬剤の使い方 (腎障害時). The Experiment&Therapy, 624;28-31, 1991.

• 4) 安藤亮一, 中川成之輔:利尿薬. 臨床透析 7 (7):46-49, 1991.

P.249 掲載の参考文献

• 1) 廣瀬賢次:糖尿病用剤, インスリン. 腎障害患者への投薬. 158-168, ミクス, 1998.

• 2) 山崎親雄, 伊藤晃:インスリン・経口血糖降下薬. 臨床透析 7 (7):198-203, 1991.

• 3) 平澤由平, 甲田豊:インスリンの用い方. 透析室薬剤の選び方と使い方. 163-164, 南江堂, 1993.

• 4) 馬場園哲也, 横山宏樹, 他:糖尿病患者におけるCAPD療法. 腎と透析 29;613-616, 1990.

P.259 掲載の参考文献

• 1) Hori R, Okumura K, Kamiya A, et al:Ampicillin and Cephalexin in renal insufficiency, Clin Pharmacol Ther 34:792-98, 1983.
  pubmed

• 2) Haberle D, Ober A, Rubland G, et al:Influence of glomerular filtration rate on the rate of paraaminohippurate secretion by the rat kidney:micropuncture and clearance studies, Kidney Inter 7:385-96, 1975.

• 3) Matzke GR, Millikin SP:Influence of renal function and dialysis on drug disposition In:Applied Pharmacokinetics (3rd ed.) Applied Therapeuties, Inc. Vancouver, WA, pp 8-18-49, 1992.

• 4) Bianchetti G, Graziani G, Brancacrio D, et al:Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment, Clin Pharmacokinet 1:373-384, 1976.

• 5) Terao N, Shen DD:Reduced extraction of 1-propranolol by perfused rat liver in the presence of uremic blood, J Pharmacol Exp Ther 233:277-284.1985.

• 6) Gambertoglio JG:Effects of renal disease:Altered Pharmacokinetics, In:Pharmacokinetic basis for drug treatment, Raven Press, NY:pp 149-171, 1984.

• 7) Reidenberg MM, Drayer DE:Alteration of drug protein binding in renal disease, Clin Pharmacokinet 9:18-26, 1984.
  pubmed

• 8) Horiuchi T, Johno I, Hosegama T, et al:Inhibitory effect of free fatty acid on plasma protein binding of disopyramid in haemodyalysis patients, Eur J Clin Pharmacol 36:175-180, 1989.

• 9) Keller F:Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodyalysis. Clin Nephrol 19:201-205, 1983.

• 10) Lee CC, Marbury TC:Drug therapy in patients undergoing hemodialysis:Clinical pharmacokinetic considerations. Clin Pharmacokinet 9:42-66, 1984.

• 11) Bennett WM, Aronoff GR, Mosison G, et al:Drug prescribing in renal failure:dosing guidelines for adults. Am J Kidney Dis 3:155-93, 1983.

• 12) Bennet WM, et al:Guide to drug dosage in renal failure. Clin Pharmacokinet 15:326-54, 1988.

• 13) Peter WL, Redic-Kill KA, Halstensen CE, et al:Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokint 22:169-210, 1992.

• 14) Welling PG, Eraig WA, Kurin CM, et al:Prediction of drug dosage in patients with renal failure using data derived from normal subjects. Clin Pharmacol Ther 18:45-52, 1975.

• 15) Jeliffe RW:Creatinine clearance:Bedside estimation. Ann Inter Med 79:604-605, 1973.

• 16) Cockroft DW, Gault MH:Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976.

• 17) Gibaldi M, Perier D:Multiple dosing ln:Pharmacokinetics (2nd ed.) Marcel Dekker, Inc. NY:pp 113-144, 1982.

• 18) Yamaoka K, Tanizawata Y, Nakagawa T, et al:A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885, 1981.

• 19) Beal SL:Estimating population kinetics. CRC Critical Reviews in Biomedical engineearing 8:195-222, 1982.

• 20) Higuchi S, Aoyama T, Horioka M, et al:PEDA:A microcomputer program for parameter estimation and dosage adjustment in clinical practice. J Pharmacobio-Dyn 10:703-718, 1987.

• 21) Sheiner LB:Methods for drug dosage individualization:Past, present and future. In:Pharmacokinetics-a modern view, Plenum Press. NY:pp 295-314, 1984.

• 22) Bauer LA:Rebound gentamicin levels after hemodialysis. Then Drug Nonit 4:99-101, 1982.

• 23) Kusafuka H, Yoshida H, Goto M:Pharmacokinetics of amikacin in hemodialysis patients:Effectiveness of dose adjustment method taking into account postdialysis concentration rebound. Jpn J TDM (in press).

P.267 掲載の参考文献

• 1) Matsuzawa Y, Tokunaga K, Kotani K, et al:Simple estimation of ideal body weight from body mass index with the lowest morbidity. Diabetes Research and Clinical Practice 10:S 159-S 164, 1990.

• 2) Lohman TG:Skinfolds and body density and their relationship to body fatness:a review. Human Biol 53:181-225, 1981.

• 3) Borah MF, Schoenfeld PY, Gotch FA, et al:Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 14:491-500, 1978.
  pubmed

• 4) Heymsfield SB, McManus C, Smith J, et al:Anthropometric measurement of muscle mass:revised equations for calculating bone-free arm muscle area. Am J Clin Nutr 36:680-690, 1982.
  pubmed

• 5) Keshaviah PR, Nolph KD, Moore HL, et al:Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 4:1475-1485, 1994.
  pubmed

• 6) Lowrie EG, Lew NL:Death risk in hemodialysis patients:The predictive values of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kid Dis 15:458-482, 1990.

• 7) 池田義和:血漿蛋白からみた栄養状態の把握, 医学のあゆみ120:324-331, 1982.

• 8) Dominioni L, Dionigi R:Immunological function and nutritional assessment. J Parenter Enteral Nutr 11 (Suppl. 5):S 705-S 725, 1987.

• 9) 前田貞亮:透析者における栄養学概論. 臨抹透析1:1785-1795, 1985.

• 10) Feinstein EI, Kopple JD:Severe wasting and malnutrition in a patient undergoing maintenance dialysis (clinical conference). Am J Nephrol 11:398-405, 1985.

• 11) わが国の慢性投石療法の現況. 日本透析医学会統計調査委員会, 1993.

• 12) Nakai S, Fujisawa T, Shinzato T, et al:Creatinine generation rate as a mortality risk factor. Blood Purifcation (Abstracts) p. 193, 1994.

• 13) 大平整爾, 阿部憲司, 長山 誠, 他:血液透析によるリン除去率・量の検討. 透析会誌21:1021-1026, 1988.

• 14) 園部美弥彦, 湯川 進, 野本 拓, 他:透析患者の動脈硬化症の進展予防. 臨林透析6:1217-1222, 1990.

II. CAPD

P.277 掲載の参考文献

• 1) Nolph KD, ed. Peritoneal Dialysis. 3rd Ed. Dordrecht:Kluwer Academic Publisher;1989.

• 2) 山下明泰, 南雲裕子, 日台英雄, 他:CAPDにおける物質拡散項と対流項の溶質輸送効果. 人工臓器14:111-114, 1985.

• 3) Bell RL, Kingsbury CF, Babb AL:Analog simulation of the patient-artificial kidney system. Trans ASAIO 6:183-189, 1965.

• 4) Popovich RP, Pyle WK, Moncrief JW:Kinetics of peritoneal transport, Pertoneal dialysis. Martinus Nijhoff Pub:79-123, 1981.

• 5) Laird NM, Berkey CS, Lowrie EG:Modelling success or failure of dialysis therapy:The National Cooperative Dialysis Study. Kidney Int 23:SIOI-106, 1983.
  pubmed

• 6) Harter HR:Review of significant findings from the National Cooperative Dialysis Study and Recommendations. Kidney Int 23:S 107-112, 1983.

• 7) Gotch FA, Sargent JA:A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 28:526-534, 1985.
  pubmed

• 8) Blake PG, Sombolos K, Abraham G, et al:Lack of correlation between urea kinetics indices and clinical outcomes in CAPD patients. Kiney Int 39:700-706, 1991.

• 9) Shinzato T, Nakai S, Maeda K, et al:Determination of creatinine generation rate using creatinine kinetic modeling and examination of its clinical significance.

• 10) 川口良人:血液透析法の実際-CAPD. 透析療法ハンドブック. 187-202, 1990.

• 11) 長沼信治, 太田和夫:CAPD療法II-CAPDの原理とシステム:1-13, 1990.

• 12) Flessner MF:Peritoneal Transport Physiology:Insights from Basic Research. J Am Nephrol 1991;2:122-135.

• 13) Rippe B, Haraldsson B:Fluid and protein fluxes across small and large pores in the microvasculature. Application of two pore equations. Acta Facial Scand 1987;131:411-428.

• 14) Rippe B, Stelin G:Simulations of peritoneal solute transport during CAPD. Application of two-pore formalism. Kidney Int 38:. 1234-1244, 1989.

• 15) Rippe B, Stein G:Simulations of peritoneal solute transport during CAPD:Application of two-pore formalism. Kidney Int 39:1234-1244, 1989.

• 16) Rippe B, Stelin G:How dose peritoneal dialysis remove small and large molecular weight solutes? Transport pathway:Fast and myth. Advances in Peritoneal Dialysis 6:13-18, 1990.

• 17) Rippe B, Simonsen O, Stelin G:Clinical implications of a three-pore model of peritoneal transport. Advances in Peritoneal Dialysis 6:3-12, 1991.
  pubmed

• 18) Rippe B, Stein G, Haraldsson B:Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 40:315-325, 1991.

• 19) Grzegorzewska AE, Moore HL, Nolph KD, et al:Ultrafiltration and effective peritoneal blood flow during peritoneal dialysis in the rat. Kidney Int 39:608-617, 1991.
  pubmed

• 20) Aune S:Transperitoneal exchange:II Peritoneal blood flow estimated by hydrogen gas clearance. Scand J Gastroenterol 5:99-104, 1970.
  pubmed

P.280 掲載の参考文献

• 1) 大漉正夫, 小川洋史, 斉藤 明, ほか:腹膜硬化症における腸間膜の超音波像, 日本超音波医学会論文集 52:135-136, 1988.

• 2) 大漉正夫, 斉藤 明, 堀口祐爾, ほか:腹膜透析患者にみられる腸間膜肥厚像の検討, 日本超音波医学会論文集 55:451-452, 1989.

• 3) 大漉正夫, 斉藤 明, 堀口祐爾, ほか:腹膜硬化症の病態に関する超音波学的検討, 日本超音波医学会論文集 56:489-490, 1990.

• 4) M OHSUKI:Ultrasonographic evaluation of mesentery in CAPD patients. CURRENT CONCEPTS IN PERITONEAL DIALYSIS:489-493, 1992.

P.285 掲載の参考文献

• 1) Johnson RC, Bock F, Knab W, et al:A model for study of the kinetics of continuous ambulatory peritoneal dialysis (CAPD). Trans. Am. Soc. Artif. Intern. Organs 29:67, 1983.

• 2) Pyle WK, Moncrief JW, Popovich RP:Peritoneal Transport Evaluation in CAPD. CAPD Update, pp.35, Masson Publishing USA Inc., 1981.

• 3) Grodstein GP, Blumenkrantz MJ, Kopple JD, et al:Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 19:564, 1981.

• 4) Widere TE, Smeby LC, Myking OL:Plasma concentrations and transperitoneal transport of native insulin and C-peptide in patients on continuous ambulatory peritoneal dialysis. Kidney Int 25:82, 1984.

• 5) 熊野和雄, 横田真二, 清水辰雄, ほか:CAPD患者における酸塩基平衡. 透析会誌 19:167, 1986.

• 6) 川口良人, 藤巻博, 尾田芳隆, ほか. CAPDと酸塩基平衡. 腎と透析 15.105, 1983.

• 7) Popovich RP, Moncrief JW, Nolph KD, et al:Continuous Ambulatory Peritoneal Dialysis. Ann Intern Med 88:449, 1978.
  pubmed

• 8) Ahearn DJ, Nolph KD:Controlled sodium removal with peritoneal dialysis. Trans. Am. Soc. Artif. Intern. Organs 18:423, 1972.
  pubmed

• 9) Nolph KD, Miller FN, Pyle WK, et al:An hypothesis to explain the ultrafiltration characteristics of peritoneal dialysis. Kidney Int 20:543, 1981.
  pubmed

• 10) 熊野和雄, 篠原克人, 飯高喜久雄, 他:CAPD療法における電解質除去特性. 透析会誌 18:167, 1985.

• 11) Delmez JA, Slatopolsky E, Martin KJ, et al:Minerals, Vitamin D, and parathyoid hormone in continuous ambulatory peritoneal dialysis. Kidney Int 21:862, 1982,

• 12) Calderaro V, Oreopoulos DG, Meema HE, et al:The evolution of renal osteodystrophy in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Proc. EDTA 17:533, 1980.

• 13) Delmez JA, Dougan CS, Gearing BK, et al:The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 31:795, 1987.
  pubmed

• 14) Fukagawa M, Kaname S, Igarashi T, et al:Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 39:874, 1991.
  pubmed

• 15) 笠井健司, 川口良人:CAPD療法と骨病変-特集 CAPDの今日, 明日. 腎と透析 28:1047, 1990.

• 16) Nilsson-Thorell CB, Muscalu N, Andrn AHG, et al:Heat sterilization of fluids for peritoneal dialysis gives rise to Aldehydes. Perit Dial Intern 13:208, 1993.

P.289 掲載の参考文献

• 1) Gejyo F, Odami S, Yamada T, et al:Beta 2 microglobulin:a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 30:385-390, 1986.

• 2) Odani H, Oyama H, Tihani K, et al:Purification and complete amino acid sequence of novel beta 2 microglobulin. Biochem Biophys Res Commun 168:1223-1229, 1990.

• 3) Linke RP, Hampl H, Lobeck H, et al:Lysin-specific cleavage of beta 2-microglobulin in amyloid deposits associated with hemodialsis. Kidney Int 36:675-681, 1993.

• 4) Miyata T, Oda O, Inagi R, et al:beta 2-microglobulin modified with advanced glycution end products is a major component of hemodialysis-associated, amyloidosis. J Clin Inves 92:1243-1252, 1993.

• 5) De Broe ME, Nouwen J, Waeleghem Jp, et al:On the welhanism and gite of production of beta 2-microglobulin during hemodialysis [letter]. Nephrol Dial Transplant 2:124-125, 1987.

• 6) Blumberg A, Burgi W:Behavior of beta 2-microglobulin in patients with chronic renal failure undergoing hemodialysis, hemodiafiltration and continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 27:245-249, 1987.
  pubmed

• 7) Sethi D, Murphy CM, Brown EA, et al:Clearance of beta 2-microglobulin using continuous ambulatory peritoneal dialysis. Nephron 52:352-355, 1989.
  pubmed

• 8) Tielemans C, Dratwa M, Bergmann P, et al:Continuous peritoneal dialysis protective against developing dialysis-associated amyloid? [letter;comment]. Nephron 53:174-175, 1989.
  pubmed

• 9) Gagnon RF, Lough JO, Bourgouin PA, et al:Carpal tunnel syndrome and amyloidosis associated with continuous ambulatory peritoneal dialysis.
  pubmed

• 10) Colombi A, Wegmann:Beta 2-microglobulin amyloidosis in a patient on long-term continuous ambulatory peritoneal dialysis. Perit Dial Int 9:321-324, 1989.

• 11) Jadoul M, Noel H, Van Ypersele de Strihon C, et al:Beta 2-microglobulin amyloidosis in a patient treated dxclusively by continous ambulatory peritoneal dialysis. Perit Dial Int 9:321-324, 1989.

• 12) Maeda K:Beta 2-microglobulin generation rate and clearance rate in maintenance hemodialysis patients. Nephron 56:118-125, 1990.
  pubmed

P.293 掲載の参考文献

• 1) わが国の慢性透析療法の現況-1992年12月31日現在. 日本透析療法学会.

• 2) Popovich RP, Moncrief JW, Nolph KD, et al:Continuous ambulatory peritoneal dialysis. Ann Intern Med 88:449, 1978.
  pubmed

• 3) Rottembourg J, Issad B, Allouache M, et al:Clinical Aspects of Continuous Ambulatory and Continuous Cyclic Peritoneal Dialysis in Diabetic Patients. Perit Dial Intern 9:289, 1989.

• 4) Flynn CT, Nanson JA:Intraperitoneal insulin with CAPD-an artificial pancreas. Trans Am Soc Artif Intern Organs 25:114, 1979.
  pubmed

• 5) Widere TE, Smeby LC, Berg KJ, et al:Intraperitoneal (1251) insulin absorption during intermittent and continuous peritoneal dialysis. Kidney Int 23:22, 1983.

• 6) 中尾俊之, 友成治夫, 宇都宮正範:糖尿病性腎症とCAPD-特集 CAPDの今日, 明日. 腎 と透析 28:1063, 1990.

• 7) Beardsworth SF, Ahmad R, Terry E, et al:Intraperitoneal insulin:A Protocol for administration during CAPD and review of published protocols. perit. dial. Intern 8:145, 1988.

• 8) Khanna R, Oreopoulos DG:Continuous ambulatory peritoneal dialysis in end-stage diabetic nephropathy. In:Diabetic nephropathy. Strategy for theraph. ed. by Friedman, EA, Peterson, CM, 105, Martinus Nijhoff Publishing, Boston, 1986.

• 9) 馬場園哲也, 横山宏樹, 佐中孜, ほか:糖尿病患者におけるCAPD療法-特集糖尿病性腎症 のすべて. 腎と透析 29:137, 1990.

• 10) 木村靖夫, 渡辺修一, 若林良則, ほか:CAPDの有用性-腎臓疾患糖尿病性腎症. 日本臨牀 50 (増刊号 血液浄化療法・下巻):186, 1992.

• 11) Canadian CAPD Clinical Trials Group.:Peritonitis in Continuous Ambulatory Peritoneal Dialysis (CAPD):A Multi-Centre Randomized Clinical Trial Comparing the Y Connector Disinfectant System to Standard Systems. Perit. Dial. Intern 9:159, 1989.

• 12) The Ad Hoc Advisory Committee on Peritonitis Management.:Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis Treatment Recommendations:1989 Update. Perit. Dial Intern 9:247, 1989.

• 13) Tranus A, Heimbrger O, Lindholm B:Peritonitis in Continuous Ambulatory Peritoneal Dialysis (CAPD):Diagnostic Findings, Therapeutic Outcome and Complications. Perit. Dial. Intern 9:179, 1989.

• 14) Rotellar C, Black J, Winchester JF, et al:Ten Years:Experience With Continuous Ambulatory Peritoneal Dialysis. Am J Kedney Dis 17:158, 1991.

• 15) Serkes KD, Blagg CR, Nolph KD, et al:Comparison of Patient and Technique Survival in Continuous Ambulatory Peritoneal Dialysis (CAPD) and Hemodialysis:Amulticenter study. Perit Dial Intern 10:15, 1990.

• 16) Brunner FP, Fassbinder W, Broyer M:Survival on renal replacement therapy:Data from the EDTA registry. Nephrol Dial Transplant 2:109, 1988.
  pubmed

• 17) 中尾俊之:糖尿病性腎不全による慢性透析患者の病像, 透析会誌 19:1061, 1986.

• 18) 川口良人, 石田裕一郎:糖尿病性腎不全のCAPD療法. 新・糖尿病性腎症, 繁田幸男, 海津嘉蔵編, p. 367, 医学書院, 東京, 1992.

P.305 掲載の参考文献

• 1) Boen ST, Mulinari AS, Dillard DH, et al:Periodic peritoneal. dialysis in the management of chronic uremia. Trans Am Soc Artif Intern. Organs 8:256, 1962.

• 2) Popovich RP, Moncrief JW, Decherd JF, et al:Definition of a novel portable wearable equilibrium dialysis technique. Abstracts Am Soc Artif Intern Organs 5:64, 1976.

• 3) Miller FN, Nolph KD, Harris PD:Microvascular and clinical effects of altered peritoneal dialysis solutions. Kidney Int 15:630, 1989.

• 4) Giordano C, deSanto NG, Plurio M:Protein requirement of patients on CAPD;A study on nitrogen balance. Int J Artif Organs 3:11, 1980.

• 5) Vas SI:Microbiological aspects of chronic amburatory peritoneal dialysis. Kidney Int 23:83, 1983.

• 6) Mion C, Slingeneyer A, Canard B:Peritonitis, in continuous amburatory peritoneal dialysis, edited by Gokal R, Edinburgh, Churchill Livingstone, p 163, 1986.

• 7) Working Party of the BSAC:Diagnosis and management of peritonitis in CAPD. Lancet 1:845, 1987.

• 8) Prowant B, Nolph KD:Five years experience with peritonitis in a CAPD program. Peritoneal Dial Bull 2:169, 1982.

• 9) Pierratos A:Peritoneal dialysis glossary. Peritoneal Dial Bull 4:2, 1984.

• 10) Verger C, Brunschweig O, Le Charpentier Y:Peritoneal sturactual alterationa in CAPD, in advances in peritoneal dialysis, edited by Gahl G, Nolph K, Kessel M, Amsterdam, Excerpta Medica, p 10, 1981.

• 11) Dobbie J, Zaki M, Wilson L:Ultrastructual studies on the peritoneum with special reference to CAPD. Scott Med J 26:213, 1981.

• 12) Verger C, Luger A, Moore J, et al:Acute changes in peritoneal morphology and transport properties with infectious peritonitis and mechanical injury. Kidney Int 23:823, 1983.

• 13) Shaldon S:Peritoneal macrophages-the first line of defence, in Peritoneal Dialysis, edited by La Greca G, Chiaramonte S, Fabris A, Feriani M, Ronco C, Milano, Wichtig Editore, p 201, 1986.

P.313 掲載の参考文献

• 1) Keane WF, et al:CAPD related peritonitis management and antibiotic therapy recommendations:Travenol Peritonitis Management Advisory Committee. Perit. Dial. Bull 7:55, 1987.

• 2) Buggy BP, Schaberg DR, Swartz RD:Intraleucocytic sequestration as a cause of persistant Staphylococcus aureus peritonitis in continuous ambulatory peritneal dialysis. Am J Med 76;1035-1040, 1984.

• 3) 透析患者への薬剤. 1991, 臨床透析 7 (7), 1991.

P.315 掲載の参考文献

• 1) Baile GR, Eisele G:Continuos ambulatory peritoneal dialysis:A review of its mechanism, advantage, complications, and area of controversy. Ann Pharmacother 26:1409-20, 1992.

• 2) Paton TW, Cornisk WR, Manuel MA, et al:Drug therapy in patients undergoing peritonea. dialysis:Clinical Pharmacokinetic considerations. Clin pharmacokinet 10:404-426, 1985.

• 3) Keller E, Reatze P, Schollmyer P:Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis:Clinical pharmacokinetic consideration. Clin Pharmaco kinet 18:104-117, 1990.

• 4) Keller E:Peritoneal kinetics of different drugs, Clin Nephrol 30:S 24-S 28, 1988.

• 5) Keane WF, Reatze P, Schollmyer P:Continuous ambulatory peritoneal dialysis (CAPD) peritonitis treatment recommendation:1989 update. Perit Dial Int 9:247-56, 1989.

• 6) Peterson P, Matzke GR, Keane WF, et al:Current concepts in the management of peritonites in patients under-going continuous ambylatory peritoneal dialysis. Rev Infect Dis 9:604-12, 1987.